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Ovarian	  and	  endometrial	  cancers	  are	  two	  of	  the	  most	  common	  gynaecological	  
malignancies	  in	  women.	  The	  chemotherapeutic	  drug	  cisplatin	  is	  a	  first-­‐line	  
therapy	  for	  both	  of	  these	  cancers,	  however	  despite	  the	  success	  of	  this	  treatment	  
there	  are	  patients	  who	  suffer	  relapse.	  This	  is	  associated	  with	  acquired	  resistance	  
of	  tumour	  cells	  to	  cisplatin	  and	  raises	  the	  need	  for	  an	  effective	  treatment	  that	  can	  
re-­‐sensitise	  the	  cancer	  to	  cisplatin.	  There	  is	  promise	  in	  targeting	  particular	  
cellular	  growth	  and	  signalling	  pathways	  that	  contain	  over	  active	  proteins,	  as	  it	  is	  
these	  that	  decide	  a	  cells	  fate	  (in	  terms	  of	  survival	  or	  death).	  This	  study	  
investigates	  the	  inhibition	  of	  both	  the	  PI3K,	  Akt,	  mTOR	  pathway	  through	  
phosphoinositide-­‐3	  kinase	  (PI3K)	  and	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway	  through	  
extracellular	  signal-­‐related	  kinase	  (ERK).	  The	  aim	  of	  the	  project	  is	  to	  re-­‐sensitize	  
cisplatin	  resistant	  cancerous	  cell	  lines	  Hec-­‐1A	  (endometrial	  adenocarcinoma)	  
and	  OVCAR-­‐5	  (ovarian	  adenocarcinoma)	  to	  cisplatin	  through	  PI3K	  and	  ERK	  
inhibition.	  The	  dual	  inhibition	  therapy	  utilized	  inhibitors	  FR180204	  and	  
LY294002	  who	  target	  ERK	  and	  PI3K	  respectively.	  This	  research	  utilized	  3D	  cell	  
culturing	  techniques,	  which	  provided	  an	  insight	  into	  the	  potential	  impact	  a	  
tumour	  cells	  microenvironment	  may	  have	  on	  the	  treatment.	  The	  results	  of	  this	  
research	  found	  no	  significant	  reduction	  in	  cellular	  metabolism	  or	  growth	  activity	  
after	  treatment	  with	  FR180204,	  LY294002	  and	  cisplatin	  (singly	  and	  in	  
combination).	  Limited	  Western	  blotting	  of	  signalling	  proteins	  suggested	  the	  
inhibitors	  had	  no	  significant	  effect	  upon	  the	  expression	  of	  ERK,	  Akt	  and	  cyclin	  B2	  
proteins	  across	  all	  combination	  treatments	  in	  OVCAR-­‐5	  cells.	  The	  information	  
provided	  in	  this	  research	  is	  capable	  of	  providing	  a	  platform	  for	  future	  studies	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ABBREVIATIONS AND DEFINITIONS 
 
AKT	   	   	   	   protein	  kinase	  B	   	  
ATP	   	   	   	   adenosine	  triphosphate	  
BAD	   	   	   	   Bcl-­‐2-­‐associated	  death	  promoter	  	  
BSA	   	   	   	   bovine	  serum	  albumin	  
Cisplatin	   	   	   cis-­‐diamminedichloroplatinum	  (II)	  
CREB	   	   	   	   CAMP	  responsive	  element	  binding	  protein	  
Crystal	  violet	   	   	   (tris(4-­‐(dimethylamino)phenyl)methylium	  chloride	  
DMEM/F-­‐12	   Dulbecco’s	  Modified	  Eagle	  Medium/Nutrient	  
Mixture	  F-­‐12	  
DMSO	   dimethyl	  sulfoxide	  
EDTA	   ethylenediaminetetraacetic	  acid	  
EGF	   	   	   	   epidermal	  growth	  factor	  
EGFR	   	   	   	   epidermal	  growth	  factor	  receptor	  
ERK	   	   	   	   extracellular	  signal-­‐related	  kinase	  
FBS	   foetal	  bovine	  serum	  
FDA	   	   	   	   Food	  and	  Drug	  Administration	  
FR180204	   	   	   ERK	  inhibiting	  compound	  
FTI	   	   	   	   farnesyltransferase	  inhibitor	  
GAPDH	   glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  
GDP	   	   	   	   guanine	  diphosphate	  
GEF	   	   	   	   guanine	  nucleotide	  exchange	  factor	  
GTP	   	   	   	   guanine	  triphosphate	  
Hec-­‐1A	   	   	   human	  endometrial	  adenocarcinoma	  cell	  line	  	  
HRP	   horseradish	  peroxidise	  
JNK	   	   	   	   c-­‐Jun	  N-­‐terminal	  kinase	  
LY294002	   	   	   PI3K	  inhibiting	  compound	  
MAPK	   	   	   	   mitogen-­‐activated	  protein	  kinase	  
MEK	   	   	   	   mitogen-­‐activated	  protein	  kinase/ERK	  kinase	  
MPSC	   	   	   	   micropapillary	  serous	  carcinoma	  
mTOR	  	   	   	   mammalian	  
 5 
NER	   	   	   	   nucleotide	  excision	  repair	  
NF-­‐κB	   nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  
activated	  B	  cells	  
OD	   optical	  density	  
OVCAR-­‐5	   	   	   human	  ovarian	  adenocarcinoma	  cell	  line	  
pAkt	   phosphorylated	  Akt	  
PDES	   	   	   	   prenyl-­‐binding	  protein	  
PDK1	   	   	   	   phosphoinositide-­‐dependent	  kinase	  1	  
pERK	   phosphorylated	  ERK	  
PI3K	   	   	   	   phosphoinositide-­‐3-­‐kinase	  
Pikk	   	   	   	   Phosphatidylinositol	  3-­‐kinase-­‐related	  kinase 
PIP2	   	   	   	   phosphatidylinositol-­‐4,5-­‐bisphosphate	  
PIP3	   	   	   	   phosphatidylinositol-­‐3,	  4,	  5-­‐triphosphate	  
PKC	   	   	   	   protein	  kinase	  C	  
PNCA	   	   	   	   proliferating	  cell	  nuclear	  antigen	  
poly-­‐HEMA	   poly-­‐hydroxyethylmethacrylate	  
PTEN	   	   	   	   phosphate	  and	  tensin	  homologue	  protein	  
PVDF	   	   	   	   polyvinyl	  difluoride	  
	  
rpm	   	   	   	   revs	  per	  minute	  
SDS	   	   	   	   sodium	  dodecyl	  sulphate	  
SDS-­‐PAGE	   sodium	  dodecyl	  sulphate	  poly-­‐acrylamide	  gel	  
electrophoresis	  
SEM	   	   	   	   standard	  error	  of	  the	  mean	  
TBS-­‐T	   Tris-­‐buffered	  saline	  and	  Tween20	  
TSC1	   	   	   	   tuberous	  sclerosis	  1	  
VEGF	   	   	   	   vascular	  endothelial	  growth	  factor	  





CHAPTER 1: INTRODUCTION 
 
1.1 Overview  
 
The	  prevalence	  of	  ovarian	  and	  endometrial	  cancer	   is	   increasing.	   It	   is	  estimated	  
that	  worldwide	  more	   than	  225,500	  women	  are	  diagnosed	  with	   ovarian	   cancer	  
each	  year	  and	  annually	   there	  are	  over	  40,000	  new	  cases	  of	  endometrial	  cancer	  
(Mabuchi	   et	   al	   2015,	   Tsoref	   et	   al	   2014).	   The	   traditional	   treatment	   for	   these	  
cancers	   includes	   a	   combination	   of	   cyto-­‐reductive	   surgery	   and	   platinum-­‐based	  
chemotherapy.	   Cytotoxic	   drugs	   used	   in	   the	   chemotherapy	   of	   ovarian	   and	  
endometrial	   cancers	   are	   relatively	   successful	   in	   eliminating	   cancerous	   cells.	  
However,	  a	  number	  of	  patients	  who	  undergo	  this	  treatment	  relapse	  afterwards,	  
indicating	   a	   resistance	   to	   this	   type	   of	   therapy	   and	   the	   need	   for	  more	   effective	  
treatment	  options	  (Karaca	  et	  al	  2013).	  Various	   ideas	  have	  been	  proposed	  as	   to	  
what	  may	  be	  causing	  this	  phenomena	  but	  one	  holds	  particular	  promise.	  This	   is	  
the	   over	   activity	   of	   particular	   proteins	   within	   cellular	   growth	   and	   signalling	  
pathways	   that	   are	   potentially	   preventing	   cancers	   subsequent	   proliferation,	  
growth	  and	  metastasis.	  	  
	  
Cisplatin-­‐induced	   DNA	   damage	   stimulates	   cellular	   growth	   and	   signalling	  
pathways,	   which	   control	   the	   activation	   of	   apoptosis;	   or	   in	   the	   case	   of	   some	  
tumour	  cells	  their	  survival.	  	  There	  is	  evidence	  that	  proteins	  such	  as	  extracellular	  
signal-­‐related	   kinase	   (ERK),	   c-­‐Jun	   N-­‐terminal	   kinase	   (JNK),	   protein	   kinase	   B	  
(Akt)	   and	   protein	   kinase	   C	   (PKC)	   are	   thought	   to	   regulate	   signals	   influencing	  
tumour	   survival	   or	   apoptosis.	   Studies	   have	   found	   that	   the	   occurrence	   of	  
mutations	   within	   key	   oncogenes	   KRAS,	   BRAF	   and	   PTEN	   have	   resulted	   in	   the	  
over-­‐activity	   of	   proteins	   found	   within	   the	   Ras,	   Raf,	   MEK,	   ERK	   and	   PI3K,	   Akt,	  
mTOR	   signalling	   cascades	   (Nakayama	   et	   al	   2008,	  Wang	   et	   al	   2000).	   The	   over	  
expression	  of	  these	  proteins	  have	  been	  shown	  to	  increase	  the	  proliferation	  and	  
metastasis	  of	  the	  tumour	  cells	  preventing	  cisplatin-­‐induced	  apoptosis	  (Brozovic	  
and	  Osmak	  2007,	  Wang	  et	  al	  2007).	  
	  
In	   2013,	   Schenk	   (2013)	   investigated	   a	   potential	   therapy	   combating	   acquired	  
cisplatin	   resistance	   through	  ERK	   inhibition.	   This	   kinase	  was	   chosen,	   due	   to	   its	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key	  role	  within	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway.	  MEK	  (mitogen-­‐activated	  protein	  
kinase),	   the	   kinase	   upstream	   from	   ERK,	   had	   shown	   promising	   results	   with	  
respect	   to	   inhibition	   studies	   in	   the	   past.	   Thus,	   this	   success	  was	   thought	   to	   be	  
applicable	   to	   ERK.	   Schenk	   (2013)	   used	   the	   ERK	   inhibitor	   FR180204	   due	   to	  
supporting	   evidence	   from	  a	   study	  by	  Ohori	   et	   al	   (2005).	  This	   study	  elucidated	  
crystal	   structures	   of	   FR180204	   and	   its	   target	   ERK	   indicating	   a	   strong	   bind	  
between	  the	  two.	  Research	  by	  Schenk	  (2013)	   found	  both	  OVCAR-­‐5	  and	  Hec-­‐1A	  
cell	  lines	  to	  be	  cisplatin	  resistant.	  	  However,	  the	  targeted	  inhibition	  of	  ERK	  with	  
FR180204	  was	  neither	  effective	  alone,	  nor	  in	  combination	  with	  cisplatin.	  Limited	  
western	  blot	  analysis	   indicated	  the	  OVCAR-­‐5	  cells	  had	  a	   low	  proportion	  of	  ERK	  
proteins	   expressed,	   a	   potential	   reason	   for	   the	   inhibitors	   lack	   of	   response.	   It	   is	  
thus	   plausible	   OVCAR-­‐5	   does	   not	   up-­‐regulate	   ERK	   as	   a	   survival	   mechanism	  
against	  cisplatin	  and	  its	  inhibition	  has	  no	  effect	  on	  diminishing	  resistance.	  
	  
The	  proposed	  project	  will	  focus	  on	  developing	  an	  appropriate	  treatment	  strategy	  
against	   cisplatin	   resistant	   gynaecological	   cancers	   using	   the	   same	  methodology	  
and	  techniques	  as	  Schenk	  (2013).	  In	  addition,	  to	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway,	  
the	  PI3K,	  Akt,	  mTOR	  pathway	  will	  be	  inhibited	  by	  LY294002	  (a	  PI3K	  inhibitor).	  
This	  was	  decided	  due	  to	  evidence	  of	  cross	  talk	  between	  both	  pathways	  as	  well	  as	  
previous	  Western	  blot	  analysis	  by	  Schenk	  (2013)	  elucidating	  the	  over	  expression	  
of	  Akt	  within	  OVCAR-­‐5	  cells	  (Engelman	  2009).	  LY294002	  (a	  PI3K	  inhibitor)	  was	  
chosen	  as	  it	  has	  been	  widely	  used	  to	  elucidate	  the	  role	  of	  PI3K	  via	  inhibition.	  As	  
well	   as	   this	   there	   are	   studies	   warranting	   its	   use,	   in	   particular	   with	   platinum	  
based	   drugs,	   and	   within	   ovarian	   and	   endometrial	   cancer	   cultures	   (Liu	   et	   al	  
2015).	  	  
	  
The	  following	  report	  is	  an	  assessment	  of	  FR180204	  and	  LY294002	  efficiency	  in	  
preventing	   cell	   growth	   and	   proliferation	  within	   cisplatin-­‐resistant	   ovarian	   and	  







1.2 Cancer  
 
Cancer	   is	   defined	   as	   uncontrollable	   and	   rapid	   cell	   proliferation,	   and	   is	   a	  
multitude	  of	  diseases	  that	  arise	  through	  a	  multi-­‐step	  mutagenic	  process.	  Effected	  
cells	  acquire	  a	  collection	  of	  properties	   induced	  by	  genetic	  alterations	  (Luo	  et	  al	  
2009,	   Xie	   et	   al	   2014).	   Known	   as	   the	   “Hallmarks	   of	   Cancer”	   this	   collection	  
includes	   self-­‐sufficient	   growth	   signals,	   insensitivity	   to	   anti-­‐growth	   signals,	  
apoptosis	   evasion,	   sustained	   angiogenesis,	   tissue	   invasion,	   metastasis	   and	  
limitless	   replicative	  potential	   (Hanahan	  and	  Weinberg	  2000).	  Additionally,	  due	  
to	   recent	   discoveries	   this	   hallmarks	   list	   now	   includes:	   evasion	   of	   immune	  
destruction,	   tumour-­‐promoting	   inflammation,	   genome	   instability	   and	  
deregulation	   of	   cellular	   energetics	   (Berdasco	   and	   Esteller	   2010,	   Hanahan	   and	  
Weinberg	  2011).	  	  
	  
The	  limitless	  replicative	  potential	  of	  cancer	  cells	  defines	  the	  disease	  as	  a	  whole,	  
making	   it	   one	   of	   the	   most	   fundamental	   cancer	   traits.	   The	   uncontrolled	  
replication	   of	   cancer	   cells	   arises	   from	   specific	  mutations	   that	   allow	   the	   escape	  
from	   numerous	   failsafe	   mechanisms	   including	   apoptosis	   (the	   bodies	   natural	  
barrier	   to	   cancer)	   and	   DNA	   damage	   checkpoints.	   This	   enables	   the	   cells	   to	  
continue	  proliferating,	  to	  propagate	  existing	  mutations	  and	  to	  acquire	  new	  ones	  
(Hahn	  and	  Weinberg	  2002,	  Luo	  et	  al	  2003,	  Su	  et	  al	  2015).	  This	  also	  encourages	  
the	   transition	   of	   benign	   tumours	   to	  malignant	   tumours,	   capable	   of	   metastasis	  
(the	  development	  of	  primary	  tumours	  spawning	  pioneer	  cells	  that	  are	  capable	  of	  
invading	  adjacent	  tissues).	  These	  tumour	  cells	  travel	  to	  distant	  sites	  throughout	  
the	   body	   and,	   if	   the	   environment	   is	   right,	   establish	   new	   metastatic	   colonies	  
(Duan	  et	  al	  2014,	  Hanahan	  and	  Weinberg	  2000).	  It	  is	  said	  that	  metastasis	  causes	  
approximately	   90%	   of	   human	   cancer	   deaths	   (Hanahan	   and	   Weinberg	   2000).	  
What	  make	  cancers	  such	  intriguing,	  yet	  fatal,	  genetic	  diseases	  are	  the	  differences	  
in	   molecular	   profile,	   histology,	   prognosis	   and	   chemo-­‐sensitivity	   of	   each	   type.	  
These	   factors	  can	  vary	  depending	  on	  the	  cancer’s	   location,	  as	  well	   the	  subtype,	  
proving	   the	   determination	   of	   cures	   to	   be	   difficult	   with	   numerous	   variables	  
involved	  within	  a	  particular	  cancer’s	  existence	  (Cheaib	  et	  al	  2015).	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The	  above	  highlights	  why	  cancer	  is	  one	  of	  the	  leading	  causes	  of	  death	  worldwide,	  
with	  8.2	  million	  deaths	  and	  14.1	  million	  new	  cancer	  cases	  arising	  in	  2012	  alone	  
(Organization	  2014).	  The	  underlying	   cause	  behind	   cancer	   cell	   generation	   is	   an	  
unstable	  genome	  and	  the	  occurrence	  of	  mutations	  within	  key	  cellular	  pathways	  
(Rytelewski	  et	  al	  2014).	  Hahn	  and	  Weinberg	  (2002)	  state	  that	  in	  humans	  at	  least	  
4-­‐6	  mutations	  are	  required	  in	  order	  for	  a	  cell	  to	  reach	  the	  state	  of	  cancer.	  With	  
respect	   to	   the	   current	  worldwide	   situation,	   these	   requirements	   are	   being	  met	  
and	  at	  a	  staggering	  pace,	  as	  it	  is	  approximated	  that	  1	  in	  3	  people	  die	  from	  cancer	  
(Organization	  2014).	  	  
	  
Furthermore,	   the	   fight	  against	   cancer	  has	  been	   increasingly	  difficult	  due	   to	   the	  
development	  of	  resistance	  to	  traditional	  chemotherapy.	  Cancer	  cells	  can	  acquire	  
the	  ability	  to	  adapt	  and	  evade	  treatments	  and	  this	  has	  become	  one	  of	  the	  biggest	  
medical	  research	  challenges	  to	  be	  overcome	  (Hanahan	  and	  Weinberg	  2011).	  	  
	  
1.3 Ovarian and Endometrial Cancers 
 
Ovarian	   and	   endometrial	   cancers	   are	   two	   of	   the	  most	   common	   gynaecological	  
malignancies,	   and	   these	   occur	   in	   the	   female	   reproductive	   system.	   The	  
reproductive	   system	   is	   situated	   in	   the	   lower	   abdomen	   and	   consists	   of	   two	  
ovaries	  connected	  by	  Fallopian	  tubes	  on	  either	  side	  of	  the	  uterus	  (or	  womb).	  The	  
uterus	   is	   positioned	   above	   the	   cervix	   and	   vagina	   (Figure	   1.1).	   	   Ovarian	   cancer	  
originates	  in	  the	  ovaries;	  these	  are	  flat,	  nodular,	  oval	  structures	  that	  are	  similar	  
in	   shape	   and	   size	   to	   almonds.	   Each	   ovary	   is	   suspended	   on	   either	   side	   of	   the	  
uterus	  by	  peritoneal	  folds	  and	  ligaments,	  and	  is	  close	  to	  the	  end	  of	  the	  Fallopian	  
tubes	   (Chen	   et	   al	   2003).	   The	   ovaries	   role	   is	   to	   produce	   the	   female	   hormones;	  
oestrogen	  and	  progesterone,	  as	  well	  as	  the	  ova	  (female	  reproductive	  cells)	  that	  
travel	  through	  the	  Fallopian	  tubes	  into	  the	  uterus.	  
	  
Endometrial	  cancer	  originates	  in	  the	  endometrial	  lining	  of	  the	  uterus.	  The	  uterus	  
is	   located	   low	   in	   the	   pelvis	   and	   is	   joined	   to	   the	   vagina	   by	   the	   cervix.	   It	   is	  
comparable	  in	  size	  and	  shape	  to	  an	  upside-­‐down	  pear.	  The	  lining	  of	  the	  uterus	  is	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called	   the	   endometrium;	   this	   is	  made	   up	   of	   several	   layers	   that	   include	   surface	  
epithelium,	  blood	  vessels,	  tissue	  space	  and	  glands.	  The	  uterus	  is	  responsible	  for	  
nurturing	   the	   fertilized	  ovum	  that	  develops	   into	  a	   foetus,	  via	   implantation	   into	  
the	   endometrium.	   Ovarian	   cancer	   is	   thought	   to	   arise	   from	   the	   epithelial	   cells	  
lining	   the	  surface	  of	   the	  ovaries	  while	  endometrial	   cancer	  arises	   from	  the	  cells	  






Figure	   1.1	   The	   female	   reproductive	   system. The	   majority	   of	   ovarian	   cancers	  
arise	  within	  the	  ovaries,	  seen	  as	  the	  small	  almond	  shaped	  organs	  on	  either	  side	  
of	   the	   uterus.	   The	   endometrium,	   or	   womb	   lining	   of	   the	   uterus	   is	   where	  
endometrial	  cancers	  arise. 
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The	   pathology	   that	   underlies	   both	   ovarian	   and	   endometrial	   cancers	   lacks	  
sufficient	  evidence,	   though	  there	  are	  several	   theories	   that	  have	  been	  proposed.	  
The	   incessant	   ovulation	   theory	   proposed	   by	   Fathalla	   (1971)	   hypothesizes	   that	  
the	   process	   of	   ovulation	   traumatizes	   the	   ovary’s	   epithelium.	   The	   constant	  
rupture	  and	  repair	  of	  this	  area	  results	  in	  increased	  cell	  division	  and	  entrapment	  
of	  cells	  in	  the	  ovary	  stroma,	  leading	  to	  the	  development	  of	  tumours	  (Hawkridge	  
2014,	  Persson	  2000).	  Several	  studies	  support	  this,	  showing	  that	  the	  shedding	  on	  
the	  ovarian	  surface	  is	  a	  crucial	  stage	  in	  the	  sequence	  of	  events	  that	  progressively	  
lead	  to	  the	  development	  of	  serous,	  endometrioid	  or	  clear	  cell	  cancers	  (Murdoch	  
and	  McDonnel	  2002,	  Vercellini	  et	  al	  2011).	  	  
	  
The	  gonadotrophin	  theory	  proposed	  by	  Persson	  (2000)	  hypothesizes	  high	  levels	  
of	   gonadotrophin	   in	   some	   females’	   increases	   the	   risk	   of	   cancer.	   This	   increase	  
could	  be	  attributed	  to	  the	  onset	  of	  menopause	  or	  premature	  ovarian	  failure	  and	  
is	  detected	  by	  receptors	  for	  gonadotrophic	  hormones	  It	  is	  thought	  the	  receptors	  
and	  gonadotrophic	  hormones	  stimulate	  growth	  of	  the	  epithelium	  and	  are	  linked	  
to	  an	   increase	   in	  proliferation	  and	  a	  decrease	   in	  apoptotic	  rates	  within	   tumour	  
cells	  (Konishi	  et	  al	  1999,	  Murdoch	  and	  McDonnel	  2002).	  
	  
With	  regards	  to	  the	  pathology	  of	  endometrial	  cancer,	  it	  has	  been	  suggested	  that	  
long	   standing	   proliferation	   of	   endometrial	   cells	   can	   lead	   to	   a	   gradual	  
development	  of	  the	  endometrium	  into	  hyperplasia	  and	  then	  the	  development	  of	  
atypical	   hyperplasia,	   thus	   potentially	   leading	   to	   cancer	   cell	   development	  
(Persson	  2000).	  Additionally,	  cancers	  like	  ovarian	  or	  endometrial	  originating	  in	  
the	  female	  reproductive	  tract	  are	  then	  directly	  exposed	  to	  processes	  and	  factors	  
such	   as	   ovulation	   and	   menstruation	   or	   high	   levels	   of	   estrogens,	   which	  
inadvertently	   may	   be	   enhancing	   their	   development	   once	   the	   cancers	   have	  
become	  established	  (Fortner	  et	  al	  2015,	  Persson	  2000).	  	  
 
Ninety	   percent	   of	   ovarian	   cancers	   are	   carcinomas,	   cancers	   that	   arise	   from	   the	  
epithelium	  of	  the	  ovary	  (Bell	  2005).	  However,	  ovarian	  cancer	  can	  also	  arise	  from	  
sex-­‐cord	   stromal	   cells	   or	   germ	   cells,	   albeit	   much	   less	   frequently	   (López	   et	   al	  
2013,	  Weiderpass	  and	  Labrèche	  2012).	  Epithelial	  ovarian	  cancers	  can	  be	  broken	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down	  into	  different	  sub-­‐types	  on	  the	  basis	  of	   their	  morphological	  appearances.	  
The	   most	   common	   is	   serous	   carcinomas	   that	   account	   for	   50-­‐70%	   of	   ovarian	  
cancers	   followed	  by,	   endometrioid	   carcinomas	   (10-­‐20%),	   clear-­‐cell	   carcinomas	  
(5-­‐10%)	   and	   mucinous	   carcinomas	   (5-­‐10%)	   (Kim	   et	   al	   2012,	   Su	   et	   al	   2015).	  
Similarly	  epithelial	   endometrial	   cancers	  are	  also	  broken	  down	   into	  histological	  
categories;	   beginning	   with	   the	   most	   common	   type	   -­‐	   endometrioid	   (80%),	  
followed	  by	  serous	  (10%)	  then	  clear-­‐cell	  carcinomas	  (10%)	  (Amant	  et	  al	  2005). 
	  
Ovarian	  and	  endometrial	  cancers	  can	  also	  be	  classified	  into	  two	  broad	  categories	  
based	   primarily	   on	   their	   histology	   and	   tumour	   grade.	   The	   tumour	   grade	   of	   a	  
cancer	   depends	   on	   the	   ratio	   of	   glandular	   or	   papillary	   structures	   versus	   solid	  
tumour	  growth	  within	  an	   individual	   tumour.	  Grade	  1	  tumours	  have	  <	  5%	  solid	  
tumour	  growth,	  grade	  2:	  5-­‐50%	  tumour	  growth	  and	  grade	  3:	  >	  50%	  solid	  tumour	  
growth	  (Silverberg	  2000).	  Both	  cancers	  are	  separated	  into	  Type	  1	  and	  Type	  2.	  
	  
Type	  1	  ovarian	   cancers	  are	  made	  up	  of	   clear-­‐cell,	   endometrioid,	  mucinous	  and	  
low-­‐grade	   serous	   carcinomas.	   These	   tumours	   generally	   have	   a	   more	   positive	  
prognosis,	   as	   their	   symptoms	   present	   sooner	   and	   thus	   are	   more	   likely	   to	   be	  
diagnosed	   earlier	   (Cheaib	   et	   al	   2015,	   Hsu	   et	   al	   2004).	   They	   are	   slow	   growing	  
tumours	  and	  tend	  to	  have	  KRAS,	  BRAF,	  PTEN	  and	  PIK3CA	  mutations	  (Thibault	  et	  
al	   2014).	   Type	   2	   ovarian	   cancers	   are	   primarily	   high-­‐grade	   serous	   carcinomas.	  
These	   are	   quick	   growing	   and	   tend	   to	   present	   their	   symptoms	   at	   a	   later	   stage.	  
Thus,	   they	   are	   generally	   more	   aggressive	   and	   are	   advanced	   at	   the	   time	   of	  
prognosis	  (Hsu	  et	  al	  2004).	  These	  tend	  to	  have	  BRCA1,	  BRCA2	  and	  p53	  mutations	  
(Thibault	  et	  al	  2014).	  	  
	  
Type	   1-­‐endometrial	   cancers	   are	   strongly	   linked	   to	   excessive	   estrogens,	   to	  
obesity	   and	   to	   hormone	   receptor	   positivity.	   They	   account	   for	   70-­‐80%	   of	  
endometrial	  cancers	  and	  are	  generally	  discovered	  at	  a	   lower	  grade	  thus	  have	  a	  
more	   favourable	   prognosis	   (da	   Silva	   et	   al	   2015,	   Network	   2013).	   Type	   2	  
endometrial	  cancers	  are	  primarily	  serous	  carcinomas	  and	  are	  more	  common	  in	  
older,	  non-­‐obese	  women.	  They	  account	   for	  10-­‐20%	  of	  endometrial	  cancers	  and	  
are	  generally	  discovered	  at	  a	  higher	  grade.	  These	  cancers	  appear	  irrespective	  of	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estrogens	   levels	  and	  have	  a	   tendency	   to	   recur	   (Dobrzycka	  et	  al	  2009,	  Network	  
2013).	  Type	  2	   is	   thought	   to	  arise	   from	  atrophic	  endometrial	   tissues,	   frequently	  
metastasise	  and	  thus	  has	  a	  poorer	  prognosis	  (Weiderpass	  and	  Labrèche	  2012).	  	  
	  
There	   are	   overlapping	   risk	   factors	   associated	   with	   ovarian	   and	   endometrial	  
cancers.	  Primarily	  these	  are	  related	  to	  a	  westernized	  lifestyle	  and	  its	  associated	  
factors,	   which	   include	   obesity,	   diabetes	   and	   lack	   of	   exercise	   (Weiderpass	   and	  
Labrèche	   2012).	   Olsen	   et	   al	   (2007)	   found	   that	   the	   risk	   of	   ovarian	   cancer	  
increases	   as	   much	   as	   30%	   in	   those	   who	   are	   obese	   compared	   to	   those	   with	   a	  
healthy	  BMI	  (Body	  Mass	  Index).	  Similarly,	  it	  has	  been	  found	  that	  approximately	  
70-­‐90%	  of	  Type	  I	  endometrial	  cancer	  patients	  are	  obese	  and	  incidence	  rates	  of	  
this	  are	  10	  times	  higher	  in	  western	  cultures	  (Kaaks	  et	  al	  2002,	  Pisani	  et	  al	  1993).	  
There	  is	  an	  increased	  risk	  of	  endometrial	  cancer	  associated	  with	  late	  menopause,	  
possibly	   due	   to	   a	   greater	   lifetime	   exposure	   to	   estrogens	   (Fader	   et	   al	   2009,	  
Persson	   2000).	   Whilst	   endometrial	   cancer	   does	   not	   have	   a	   strong	   familial	  
influence,	  ovarian	  cancer	  does	  have	  a	  high	  risk	  of	  familial	  heredity,	  as	  having	  two	  
or	  more	  first-­‐degree	  relatives	  with	  the	  cancer	  significantly	   increases	  the	  risk	  of	  
developing	   it.	   About	   10%	   of	   ovarian	   cancer	   patients	   are	   likely	   to	   have	   had	   a	  
genetic	  predisposition	  to	  the	  disease	  (Modan	  et	  al	  2001).	  
	  
Approximately	  70%	  of	  ovarian	  cancer	  cases	  are	  diagnosed	  at	  an	  advanced	  stage,	  
which	   causes	   the	   risk	   of	   recurrence	   after	   treatment	   to	   be	   as	   much	   as	   60%	  
(Mabuchi	   et	   al	   2015,	   Spiliotis	   et	   al	   2015).	   Due	   to	   this	   high	   rate	   of	   advanced	  
tumours	   upon	   diagnosis,	   50%	   of	   women	   do	   not	   survive	   more	   than	   5	   years	  
(Coleman	   et	   al	   2011).	   The	   key	   factor	   causing	   this	   is	   the	   difficulty	   to	   detect	  
ovarian	   cancer	   at	   an	   early	   stage,	   due	   to	   its	   vague	   clinical	   symptoms	   (Su	   et	   al	  
2015).	   In	  comparison,	  around	  80-­‐85%	  of	  endometrial	  cancers	  are	  caught	  early,	  
giving	   a	   70-­‐80%	   chance	   of	   survival	   after	   five	   years	   of	   diagnosis	   (Amant	   et	   al	  
2005,	   Eskander	   and	  Tewari	   2014,	  Network	  2013).	   Similarly	   to	   ovarian	   cancer,	  
the	   majority	   of	   patients	   with	   aggressive,	   advanced	   endometrial	   tumours	   will	  
have	  spread	  beyond	  the	  uterus	  within	  a	  year	  of	  diagnosis	  (Network	  2013).	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Although	  there	  is	  focus	  on	  finding	  therapies	  and	  treatments	  for	  this	  disease,	  the	  
death	  rate	  of	  both	  cancers	  have	  not	  changed	  significantly	  over	  the	  last	  50	  years	  
(Lau	   and	   Leung	   2012,	   Vaughan	   et	   al	   2011).	   An	   area	   of	   research	   that	   remains	  
promising	   is	   the	  genomic	   instability	  of	   tumours	  and	  how	  mutations	  within	   the	  
genomes	  may	  provide	  targets	  for	  cancer	  treatment.	  	  
 
1.4 Oncogenes  
 
One	  of	  cancers	  fundamental	  characteristics	  is	  genomic	  instability	  and	  mutation;	  
this	   distinguishes	   tumours	   cells	   from	   their	   normal	   counterparts.	   This	   lack	   of	  
integrity	   in	   the	   cancer	   genome	   is	   often	   precipitated	   by	   mutations	   leading	   to	  
compromised	  or	  incomplete	  DNA	  repair	  (Rytelewski	  et	  al	  2014).	  This	  can	  lead	  to	  
the	   development	   of	   oncogenes,	   which	   encode	   proteins	   controlling	   cell	  
proliferation,	   apoptosis	   or	   both,	   causing	   the	   deregulation	   of	   growth	   and	  
signalling	  pathways	  in	  resuming	  tumours	  (Hanahan	  and	  Weinberg	  2000).	  
	  
When	  an	  oncogene	  is	  affected	  by	  mutation,	  the	  encoded	  protein	  will	  change	  in	  a	  
way	   that	   enhances	   or	   reduces	   its	   activity.	   For	   example,	   Ras	   oncogenes	   when	  
mutated	   at	   codons	   12,	   13	   or	   61	   remain	   in	   an	   active	   state,	   continuously	  
transducing	  signals	   to	  downstream	  kinases,	   involved	   in	  continuous	  cell	  growth	  
(Croce	  2008,	  Mayr	  et	  al	  2006,	  Nakayama	  et	  al	  2008).	  Mutations	  of	  the	  KRAS	  gene	  
have	  been	  involved	  in	  the	  development	  of	  numerous	  ovarian	  malignancies,	  with	  
reports	   of	   KRAS	  mutations	   in	   35%	   of	   ovarian	   invasive	   micropapillary	   serous	  
carcinomas	  (MPSCs)	  (Dobrzycka	  et	  al	  2009,	  Singer	  et	  al	  2003).	  The	  mutation	  in	  
codon	   12	   of	  KRAS	   has	   also	   been	   found	   in	   10-­‐30%	   of	   endometrial	   carcinomas	  
(Dobrzycka	  et	  al	  2009,	  Ryan	  et	  al	  2005).	  	  
	  
Another	   common	   mutation	   found	   in	   ovarian	   and	   endometrial	   carcinomas	   is	  
BRAF.	  Mutations	  within	   the	  Raf	   oncogene	  are	   thought	   to	  be	  present	   in	  40%	  of	  
human	   melanomas,	   affecting	   the	   structures	   of	   the	   B-­‐raf	   protein,	   resulting	   in	  
constitutive	   signalling	   down	   the	   mitogen	   activated	   protein	   (MAP)-­‐kinase	  
pathway	   (Hanahan	   and	   Weinberg	   2011,	   Nakayama	   et	   al	   2008).	   Singer	   et	   al	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(2003)	   found	   BRAF	   mutations	   in	   33%	   of	   MPSCs,	   and	   24%	   of	   ovarian	  
endometrioid	  carcinomas.	  The	  point	  mutation	  V600E	  is	   thought	  to	  be	  the	  most	  
common	  site	  of	  BRAF	  mutations	  in	  ovarian	  cancer	  (Nakayama	  et	  al	  2008,	  Sieben	  
et	   al	   2004,	   Singer	   et	   al	   2003).	   This	   mutation	   leads	   to	   changes	   within	   B-­‐raf’s	  
kinase	   domain,	   constitutively	   activating	   the	   protein	   and	   uncontrollably	  
stimulating	  MAPK	  cascades	  downstream,	  promoting	  G1/S	  transition	  of	  cell	  cycle	  
regulation	  (Croce	  2008,	  Davies	  et	  al	  2002,	  Mayr	  et	  al	  2006).	  	  
	  
In	   a	   study	   by	   Hsu	   et	   al	   (2004)	   it	   was	   reported	   that	   either	   BRAF	   or	   KRAS	  
mutations	  were	  present	  in	  approximately	  60%	  of	  ovarian	  serous	  borderline	  and	  
low-­‐grade	   serous	   tumours.	   The	   Ras,	   Raf,	   MEK,	   ERK	   pathway	  was	   found	   to	   be	  
active	   in	   33%	   of	   ovarian	   carcinomas	   in	   and	   its	   activation	   depended	   on	   the	  
mutational	   status	   of	   K-­‐ras	   and	   B-­‐raf.	   This	   highlights	   the	   influence	   these	  
oncogenes	  have	  on	  the	  growth	  of	   tumour	  cells	  (Nakayama	  et	  al	  2008).	  None	  of	  
the	  tumours	  investigated	  by	  Singer	  et	  al	  (2003)	  contained	  both	  KRAS	  and	  BRAF	  
mutations,	   which	   appears	   to	   be	   a	   common	   theme	   across	   a	   majority	   of	   the	  
literature	  (Mayr	  et	  al	  2006,	  Rajagopalan	  et	  al	  2002).	  	  
	  
PTEN	  (phosphatase	  and	  tensin	  homolog)	  is	  a	  tumour	  suppressor	  protein,	  which	  
acts	   as	   a	   negative	   regulator	   for	   the	   PI3K,	   Akt,	   mTOR	   pathway	   (Eskander	   and	  
Tewari	  2014).	  When	  a	  mutation	  is	  present	  within	  the	  PTEN	  oncogene	  this	  results	  
in	   the	   “silencing”	   of	   the	   protein	   and	   ultimately	   leads	   to	   an	   increase	   in	  
phosphorylation	  and	  the	  activation	  of	  Akt	  (Eskander	  and	  Tewari	  2014,	  Ying	  et	  al	  
2015).	  PTEN	  and	  other	  autophagy	  related	  genes	  are	  expressed	  in	  normal	  ovarian	  
tissues,	  benign	  ovarian	  tumours	  and	  borderline	  tumours,	  but	  are	  down	  regulated	  
in	  the	  cases	  of	  malignant	  ovarian	  cancers	  (Ying	  et	  al	  2015).	  PTEN	  mutations	  have	  
been	  found	  in	  20%	  of	  ovarian	  endometrioid	  carcinomas	  (Cheaib	  et	  al	  2015,	  Ryan	  
et	   al	   2005,	   Singer	   et	   al	   2003).	   As	  well	   as	   this,	   40-­‐80%	   of	   Type	   1	   endometrial	  
cancer	   cases	   have	   one	   or	   more	   somatic	   alterations	   affecting	   this	   pathway	  
(Chitcholtan	   et	   al	   2013,	   Eskander	   and	   Tewari	   2014).	   The	   expression	   of	  KRAS,	  
BRAF	   and	   PTEN	   oncogenes	   within	   these	   growth	   and	   signalling	   pathways	   of	  
ovarian	  and	  endometrial	  cancer	  raises	  the	  potential	  for	  research	  to	  focus	  in	  this	  
 16 
area.	  There	  is	  an	  opportunity	  to	  inhibit	  the	  downstream	  actions	  of	  the	  pathways	  
preventing	  the	  uncontrollable	  growth	  of	  tumours	  they	  cause.	  
	  
1.5 Cisplatin and Acquired Resistance  
 
Ovarian	   and	   endometrial	   cancers	   are	   typically	   treated	   with	   cytoreductive	  
surgery	  and	  platinum-­‐based	  chemotherapies	  (Mabuchi	  et	  al	  2015,	  Spiliotis	  et	  al	  
2015).	  The	  major	  goal	  of	  chemotherapy	   is	   to	  commit	   tumour	  cells	   to	  apoptosis	  
following	  exposure	  to	  the	  anti-­‐tumour	  agents.	  One	  of	  these	  anti-­‐tumours	  agents	  
is	  the	  platinum	  based	  drug,	  cisplatin.	  Cisplatin	  or	  cis-­‐diamminedichloroplatinum	  
is	   a	   neutral,	   inorganic,	   square	   planar	   complex,	   which	   reacts	   with	   DNA	   via	  
interaction	  with	  the	  nucleophilic	  N-­‐7	  sites	  of	  purine	  bases,	  forming	  DNA-­‐protein	  
and	  DNA-­‐DNA	  intrastrand	  or	  interstrand	  crosslinks	  (Figure	  1.2)	  (Siddik	  2003).	  	  
	  
An	  Italian	  chemist,	  Michele	  Peyrone	  in	  1845,	  first	  described	  cisplatin	  and	  it	  was	  
Rosenberg	  and	  Vancamp	  (1969)	  who	  first	  suggested	  cisplatin	  for	  clinical	  use	  in	  
1965,	   when	   examining	   the	   effect	   of	   electromagnetic	   fields	   on	   bacterial	   cell	  
growth.	  It	  was	  reported	  that	  cisplatin	  inhibited	  bacterial	  cell	  division,	  which	  then	  
led	   to	   the	  prediction	   that	   it	  would	   act	   similarly	   in	   cancer	   cells,	   and	   inhibit	   the	  
proliferation	  of	   rapidly	  dividing	   cells	   (Rosenberg	  and	  Vancamp	  1969).	   In	  1968	  
this	   was	   shown	   to	   be	   the	   case,	   with	   platinum-­‐based	   compounds	   shown	   to	  
inhibiting	   sarcoma-­‐180	   growth	   in	   mice	   (Rosenberg	   and	   Vancamp	   1969).	   The	  
first	  patients	  were	  treated	  intravenously	  with	  cisplatin	  in	  1971,	  via	  a	  short-­‐term	  
infusion	   in	   physiological	   saline	   and	   by	   1978,	   the	   cytotoxic	   drug	   was	   FDA	  
approved	  (Galluzzi	  et	  al	  2012,	  Kelland	  2007).	  	  
 
Cisplatin	   works	   as	   a	   chemotherapeutic	   agent	   through	   binding	   to	   DNA	   and	  
causing	   damage	   via	   cross-­‐linking.	   The	   DNA	   damage	   signals	   are	   transduced	  
downstream	  resulting	  in	  G1	  arrest	  in	  cell	  division	  and	  apoptosis	  (Siddik	  2003).	  It	  
has	  been	  suggested	  that	  the	  cisplatin	  adducts	  sequester	  transcription	  factors	  at	  
the	  site	  of	  cross-­‐linking	  preventing	  their	  participation	  in	  transcription	  and	  thus	  
potentially	  serving	  as	  a	  trigger	  for	  transducing	  DNA	  damage	  signals	  (N'soukpoé-­‐





Figure	  1.2	  Cisplatin’s	  mode	  of	  action.	  Cisplatin	  interacts	  with	  N-­‐7	  sites	  of	  purine	  
bases	   (blue)	   in	   DNA	   (orange)	   to	   form	   DNA-­‐protein	   and	   DNA-­‐DNA	   interstrand	  
and	  intrastrand	  cross-­‐links.	  This	  leads	  to	  recognition	  of	  DNA	  damage	  by	  proteins	  
within	  the	  cell	  and	  results	  in	  DNA	  damage	  signals	  being	  transduced.	  	  
	  
Cisplatin	  has	  been	  shown	  to	  be	  one	  of	  the	  most	  efficacious	  agents	  against	  ovarian	  
and	  endometrial	  cancers,	  with	  initial	  response	  rates	  in	  patients	  varying	  from	  40-­‐
80%.	   However,	   as	   time	   has	   progressed	   other	   platinum-­‐based	   drugs,	   including	  
carboplatin	   and	  oxaliplatin	  have	  been	   favoured	   for	   use	   (Kelland	  2007).	   This	   is	  
due	  to	  cisplatin’s	  toxicity,	  which	  can	  lead	  to	  side	  effects,	  including	  nephrotoxicity,	  
neurotoxicity	   and	   to	   a	   lesser	   extent,	   cardiotoxicity	   (Basu	   and	   Krishnamurthy	  
2010,	  Yellepeddi	  et	  al	  2011).	  Another	  reason	  cisplatin’s	  popularity	  has	  declined	  
is	   due	   to	   an	   increase	   in	   relapse	   frequency	   in	   cancer	   patients	   treated	  with	   the	  
cytotoxic	  drug	  (Nakayama	  et	  al	  2008).	  Thus	  second-­‐generation	  platinum-­‐based	  
compounds	   were	   developed	   to	   reduce	   the	   side	   effects	   of	   cisplatin	   whilst	  
retaining	   its	   anti-­‐cancer	   properties	   (Galluzzi	   et	   al	   2012,	   Parmar	   et	   al	   2003).	  
Fewer	   than	  25%	  of	  women	  diagnosed	  with	  advanced	  ovarian	  cancer	  will	   show	  
progression-­‐free	   survival	   after	   4	   years,	   in	   spite	   of	   treatment.	   This	   has	   been	  
attributed	  to	  the	  disease’s	  aggressive	  nature	  given	  that	  diagnosis	  typically	  occurs	  
at	   an	   advanced	   stage,	   but	   also	   due	   to	   the	   cancers	   reduction	   in	   sensitivity	   to	  
cisplatin	  after	  treatment	  (Bamias	  et	  al	  2012,	  Du	  and	  Ho	  2001,	  Sherman-­‐Baust	  et	  
al	   2003).	   Despite	   cisplatin’s	   replacement	   with	   newer	   platinum-­‐based	   drugs,	  
these	   also	   have	   their	   limitations.	   An	   example	   of	   this	   is	   carboplatin	   who	   has	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reduced	   toxic	   side	   effects	   in	   comparison	   to	   cisplatin,	   but	   does	   not	   cause	   a	  
response	   in	   cisplatin	   resistant	   cancers	   (Parmar	  et	  al	  2003).	  As	   such	   the	  5-­‐year	  
survival	  rates	  of	  patients	  with	  ovarian	  and	  endometrial	  cancers	  can	  be	  less	  than	  
15%.	  This	  is	  attributed	  to	  a	  combination	  of	  the	  diseases’	  aggressiveness	  and	  the	  
first	   line	  chemotherapies	  utilized	   lacking	  efficacy	   (Bamias	  et	  al	  2012,	  Eskander	  
and	  Tewari	  2014,	  Nakayama	  et	  al	  2008).	  	  
	  
The	  efficacy	  of	  cisplatin	  depends	  on	  the	  cancer	  cells	  ability	  to	  detect	  and	  respond	  
to	  DNA	  damage.	  Following	  cisplatin	  induced	  DNA	  damage;	  both	  pro-­‐survival	  and	  
pro-­‐apoptotic	  signals	  are	  activated	  simultaneously.	  The	  relative	  intensity	  and/or	  
duration	   of	   each	   are	   integrated	   downstream	   to	   determine	   the	   final	   fate	   of	   the	  
cell.	  This	   is	  very	   important	   in	   terms	  of	   resistance.	  Cells	  will	  undergo	  apoptosis	  
only	  when	  DNA	  repair	  is	  incomplete,	  as	  would	  be	  the	  case	  when	  damage	  (caused	  
by	   the	   cisplatin)	   is	   extensive	   (Singer	   et	   al	   2003).	   DNA	   damage	   via	  
chemotherapeutic	   agents	   is	   used	   to	   exploit	   DNA	   fidelity	   in	   an	   effort	   to	  
preferentially	   push	   tumour	   cells	   towards	   to	   apoptosis.	   However,	   tumour	   cells	  
with	   intact	   DNA	   repair	   pathways	   are	   less	   sensitive	   to	   this	   strategy	   and	   are	  
capable	  of	  acquiring	  resistance	  by	  outgrowth	  of	  clonal	  populations	  (Rytelewski	  
et	  al	  2014).	  	  
	  
There	   are	  many	   theories	   behind	   what	  may	   allow	   cells	   to	   survive	   and	   acquire	  
resistance.	  Mechanisms	  underlying	  tumour	  resistance	  to	  cisplatin	  are	  suggested	  
to	  be	  multi-­‐factorial,	  these	  include:	  decreased	  drug	  transport	  and	  accumulation,	  
increased	  cellular	  detoxification	  due	   to	   increased	  glutathione	   levels,	  changes	   in	  
DNA	  repair	  involving	  increased	  nucleotide	  excision	  repair	  (NER)	  and/or	  loss	  of	  
mismatch	   repair,	   increased	   tolerance	   of	   DNA	   adducts	   and	   alterations	   in	   the	  
apoptotic	   cell	   death	   pathway	   (Du	   and	   Ho	   2001,	   Eskander	   and	   Tewari	   2014,	  
Holford	  et	  al	  2000,	  Parker	  et	  al	  1991,	  Siddik	  2003).	  	  
	  
In	   response	   to	   therapy,	   cancer	   cells	   have	   the	   potential	   to	   reduce	   their	  
dependence	   on	   a	   particular	   hallmark	   capability,	   becoming	  more	   dependent	   on	  
another	   (Hanahan	   and	   Weinberg	   2000).	   Resistance	   mechanisms	   arise	   as	   a	  
consequence	   of	   intracellular	   changes	   that	   either	   prevents	   cisplatin	   from	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interacting	   with	   DNA,	   interfere	   with	   DNA	   damage	   signals	   from	   activating	   the	  
apoptotic	  machinery	  or	  both	  (Siddik	  2003).	  The	  cancer	  cells	  are	  able	  to	  survive	  
DNA	  damage	  and	   this	  may	  occur	  via	  multiple	  overactive	  growth	  and	  signalling	  
pathways,	   promoting	   proliferation,	   thus	   preventing	   apoptosis	   from	   occurring	  
(Eastman	  and	  Schulte	  1988,	  Siddik	  2003).	  Several	  signalling	  pathways	  including	  
PI3K,	   ERK,	   JNK	   and	   p38	   MAPK	   can	   regulate	   cisplatin-­‐induced	   apoptosis,	   thus	  
these	   could	   be	   potential	   targets	   with	   regards	   to	   new	   therapies	   that	   combine	  
chemotherapy	  and	  inhibitory	  agents	  (Basu	  and	  Krishnamurthy	  2010,	  Galluzzi	  et	  
al	   2012,	  Nakayama	  et	   al	   2008).	   Strategies	   to	   sensitise	   cancer	   cells	   to	  platinum	  
agents	   are	   of	   high	   clinical	   importance	   (Rytelewski	   et	   al	   2014).	   Combining	  
cisplatin	  with	  molecular	  targeted	  therapy	  has	  the	  potential	  to	  lower	  the	  dosage	  
of	  cisplatin	  currently	  employed,	  thus	  helping	  in	  alleviating	  its	  side	  effects	  as	  well	  
as	   overcoming	   platinum	   resistance	   in	   ovarian	   and	   endometrial	   cancers	   (Basu	  
and	  Krishnamurthy	  2010,	  Karaca	  et	  al	  2013).	  	  
 
1.6 The Ras, Raf, MEK, ERK signalling pathway  
	  
The	   transmission	   of	   extracellular	   signals	   into	   the	   nucleus	   is	   mediated	   by	   a	  
network	   of	   proteins	   and	   pathways	   (Seger	   and	   Krebs	   1995).	   One	   of	   these	  
pathways	  is	  the	  evolutionarily	  conserved	  Ras,	  Raf,	  MEK,	  ERK	  signalling	  cascade	  
(Samatar	   and	   Poulikakos	   2014).	   Under	   physiological	   conditions,	   this	   pathway	  
integrates	   extracellular	   signals	  with	   the	   transcription	   of	   genes	   involved	   in	   cell	  
proliferation,	   differentiation	   and	   survival	   (Ohori	   et	   al	   2005,	   Siddik	   2003).	   In	  
tumour	  cells,	  proteins	  within	  the	  pathway	  can	  be	  mutated	  causing	  deregulation	  
or	   over-­‐expression,	   leading	   to	   progression	   in	   tumour	   growth	   and	   signalling	  
(Singer	  et	  al	  2003).	  	  
	  
The	   Ras,	   Raf,	   MEK,	   ERK	   signalling	   pathway	   is	   initiated	   when	   an	   extracellular	  
signalling	   molecule	   such	   as	   epidermal	   growth	   factor	   (EGF)	   binds	   to	   the	  
epidermal	   growth	   factor	   receptor	   (EGFR)	  on	   the	   cell	   surface	   (Figure	  1.3).	   This	  




Figure	  1.3	  Overview	  of	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway. An	  extracellular	  
molecule	  (green)	  binds	  to	  its	  respective	  receptor	  (red),	  which	  spans	  the	  plasma	  
membrane.	  The	  active	  receptor	  stimulates	  Ras’	  (blue)	  exchange	  of	  GDP	  for	  GTP	  
and	  once	  active,	  recruits	  Raf	  (orange)	  to	  the	  plasma	  membrane.	  Raf	  is	  activated	  
by	  Ras	  and	  then	  phosphorylates	  MEK	  (purple)	  at	  a	  serine	  or	  threonine	  residue,	  
which	  activates	  it.	  Phosphorylated	  MEK	  (pMEK)	  then	  goes	  on	  to	  activate	  the	  final	  
protein	  in	  the	  part	  of	  the	  pathway	  that	  is	  shown,	  ERK	  (pink)	  again	  via	  
serine/threonine	  residues.	  ERK	  has	  a	  variety	  of	  downstream	  targets,	  which	  are	  
involved	  in	  cellular	  proliferation	  and	  survival.	  Image	  adapted	  from	  Schenk	  
(2013).  
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the	   conformation	   of	   a	   GTPase	   such	   as	   Ras,	   enabling	   the	   exchange	   of	   GDP	  
(guanosine	   diphosphate)	   for	   GTP	   (guanosine	   triphosphate).	   Ras	   (a	   small	  
GTPase)	   has	   three	   isoforms;	   K-­‐Ras,	   N-­‐Ras	   and	   H-­‐Ras	   (Baines	   et	   al	   2011).	   The	  
best	  understood	  GEF	   for	  Ras	   is	   the	  SOS	  (Son	  of	  Sevenless)	  protein.	  Fusing	  Ras’	  
CAAX	  motif	  to	  the	  C-­‐terminus	  of	  SOS	  renders	  Ras	  constitutively	  active	  (Burns	  et	  
al	  2014).	  Mammalian	  Ras	  proteins	  in	  active	  state	  bind	  and	  activate	  several	  other	  
effectors	   in	   addition	   to	   Raf	   kinases,	   each	   shown	   to	   play	   a	   role	   in	   Ras-­‐driven	  
cancers.	   Once	   active,	   Ras	   recruits	   Raf	   to	   the	   plasma	   membrane	   for	   its	  
dimerisation	  and	  activation.	  Raf	  is	  a	  serine/threonine	  kinase,	  meaning	  it	  can	  only	  
phosphorylate	   another	   protein	   or	   substrate	   on	   either	   a	   serine	   or	   a	   threonine	  
residue.	  There	  are	  three	  isoforms	  of	  the	  Raf	  protein	  A-­‐Raf,	  B-­‐raf	  and	  C-­‐raf.	  Once	  
Raf	   is	   activated,	   it	   seeks	   its	  main	   target,	   another	   serine/threonine	   kinase	  MEK	  
(mitogen-­‐activated	  protein	  kinase	  kinase).	  Active	  MEK	  goes	  on	  to	  phosphorylate	  
the	  final	  protein	  in	  the	  pathway	  ERK	  (extracellular	  signal-­‐related	  kinase).	  ERK	  is	  
yet	  another	  serine/threonine	  kinase,	  and	  is	  a	  key	  regulatory	  protein	  within	  the	  
cascade,	   having	   over	   160	   downstream	   targets.	   These	   targets	   include	  
transcription	   factors	   and	  proteins	   involved	   in	   cell	   cycle	   regulation,	   cell	   growth	  
and	   differentiation	   (McCubrey	   et	   al	   2007,	   Nakayama	   et	   al	   2008,	   Ohori	   et	   al	  
2005).	  	  
 
It	   is	   well	   known	   that	   components	   of	   this	   pathway	   are	   frequently	   mutated	   in	  
tumour	   cells	   (Roberts	   and	   Der	   2007).	   As	   mentioned	   prior,	   the	   proteins	   most	  
commonly	  over-­‐expressed	  are	  Ras	  and	  Raf,	   in	  particular	  the	  isoforms	  B-­‐raf	  and	  
K-­‐ras.	  Ras	  signalling	  is	  frequently	  deregulated	  in	  a	  third	  of	  human	  cancers.	  This	  
does	  not	  come	  as	  a	  surprise	  as	  KRAS	  mutations	  can	  prevent	  the	  essential	  switch	  
of	   GTP	   to	   GDP	   in	   the	   Ras	   protein,	   evidently	   leading	   to	   the	   constitutive	   hyper-­‐
activation	   of	   Ras	   and	   consequently	   of	   those	   downstream	   (Turacli	   et	   al	   2015).	  
Whilst	   Raf	   signalling	   in	   particular	   signals	   involving	   mutant	   B-­‐raf	   proteins,	  
increase	  the	  activity	  of	  downstream	  proteins	  and	  are	  amongst	  the	  most	  common	  
in	  human	  cancers	  (Davies	  et	  al	  2002).	  	  
 
These	  mutations	  both	  have	  influences	  upon	  the	  expression	  of	  ERK	  who	  controls	  
a	  wide	  range	  of	  cellular	  processes	   that	  remain	  under	  strict	  regulation.	  There	   is	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evidence	   showing	   that	   the	   over	   expression	   of	   ERK	   occurs	   in	   cancers	   is	   due	   to	  
upstream	   protein	   deregulation	   and	   this	   could	   influence	   cisplatin-­‐acquired	  
resistance	  (Zhang	  and	  Gu	  2014).	  Losing	  the	  regulation	  of	  key	  proteins	  like	  ERK	  
can	   give	   tumour	   cells	   the	   ability	   to	   evade	   cisplatin-­‐induced	   apoptosis	   through	  
constitutively	   active	   anti-­‐apoptotic	   signals	   and	   up-­‐regulated	   cellular	  
proliferation	   (Hsu	  et	  al	  2004,	  Karaca	  et	  al	  2013,	  Ohori	   et	   al	  2005,	  Turacli	   et	   al	  
2015).	  	  
	  
This	   above	   raises	   the	   possibility	   of	   using	   the	   Raf,	   Ras,	   MEK,	   ERK	   signalling	  
cascade	  as	  a	  target	  for	  cancer	  treatment,	  in	  particular	  inhibiting	  its	  activity	  to	  re-­‐
sensitise	  ovarian	  and	  endometrial	  cells	  to	  cisplatin	  (Karaca	  et	  al	  2013,	  Ohori	  et	  al	  
2005).	  	  
	  
1.7 Ras, Raf, MEK, ERK pathway inhibitors  
 
There	   are	   a	   variety	  of	   inhibitors	   that	   target	  proteins	  within	   the	  Ras,	  Raf,	  MEK,	  
ERK	  signalling	  cascade.	  Some	  of	  these	  have	  been	  around	  for	  a	   long	  time,	  whilst	  
others	  are	  newly	  developed	  or	  are	  at	  various	  junctures	  of	  clinical	  trials.	  	  
	  
As	   a	   first	   step	   in	   targeting	   this	   pathway,	   is	   inhibiting	   Ras.	   To	   date	   there	   have	  
been	  few	  reports	  of	  an	  effective	  inhibitor.	  This	  task	  has	  been	  challenging	  due	  to	  
Ras’	   substrate	   binding	   interface	   being	   structurally	   featureless.	   This	   limits	  
targeting	   the	   protein,	   as	   it	   cannot	   be	   specifically	   inhibited,	   as	   there	   are	   few	  
unique	  structural	  target	  sites	  due	  to	  similarities	  to	  other	  proteins.	  Additionally,	  
Ras’	   affinity	   for	   GTP	   is	   much	   higher	   than	   that	   of	   other	   kinases	   for	   ATP,	   thus	  
attempts	   to	   interfere	   with	   its	   nucleotide-­‐binding	   pocket	   have	   proven	   difficult	  
(Baines	  et	  al	  2011,	  McCormick	  2016,	  Young	  et	  al	  2009).	  Nevertheless,	  there	  have	  
been	  several	  strategies	  that	  have	  been	  developed	  to	  overcome	  these	  difficulties.	  
The	   first	  option	   is	   to	  prevent	  Ras’	  attachment	   to	   the	  plasma	  membrane	  and	   its	  
subsequent	  activation.	  Zimmermann	  et	  al	  (2013)	  achieved	  this	  via	  blocking	  the	  
farnesylation	  of	  Ras	  through	  farnesyltransferase	  inhibitors	  (FTI).	  Ras	  undergoes	  
several	  post-­‐translational	  modifications	  that	  facilitate	  its	  attachment	  to	  the	  inner	  
surface	   of	   the	   plasma	   membrane.	   The	   first	   modification	   is	   adding	   a	   farnesyl	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isoprenoid	   moiety	   catalysed	   by	   farnesyltransferase.	   Inhibiting	   this	   enzyme	  
prevents	   Ras	   from	   maturing	   into	   its	   active	   form	   thus	   inhibiting	   the	   entire	  
pathway	   (Li	   et	   al	   2012).	   Tipifarnib	   is	   an	   example	   of	   an	   FTI.	   It	   causes	   an	  
accumulation	  of	  cells	  in	  G1/M	  phase	  of	  the	  cell	  cycle,	  and	  induces	  apoptosis	  in	  a	  
variety	  of	  tumour	  cell	  lines	  irrespective	  of	  Ras	  mutation	  status	  (Andreopoulou	  et	  
al	  2013).	  Leshchiner	  et	  al	   (2014)	   found	   that	  SAH-­‐SOS1	  peptides	   can	   target	   the	  
SOS-­‐1	  binding	  pocket	  on	  K-­‐ras	  and	  block	  nucleotide	  association,	  impairing	  KRAS	  
driven	  cancers	  cells.	  This	  strategy	  is	  still	  being	  explored,	  Burns	  et	  al	  (2014)	  and	  
Evelyn	  et	  al	   (2014)	   found	   this	  method	   to	  be	  successful	   in	   the	   inhibition	  of	   this	  
protein	  as	  well	  as	  the	  down	  regulation	  of	  the	  following	  pathway.	  All	  of	  the	  above	  
provide	  an	  opportunity	  for	  the	  development	  of	  a	  specific	  Ras	  inhibitor	  to	  target	  
cancer	  treatment	  but	  as	  of	  now	  development	  and	  trials	  continue.	  	  
	  
Raf	   is	   the	   second	   protein	   within	   the	   signalling	   cascade.	   This	   protein	   can	   be	  
inhibited	   by	   Sorafenib,	   which	   was	   the	   first	   Raf	   inhibitor	   to	   have	   gained	  
regulatory	   approval,	   despite	   its	   weak	   specificity	   to	   B-­‐raf	   (Eisen	   et	   al	   2006).	  
Alternatively	  another	  inhibitor	  that	  has	  been	  approved	  is	  Vemurafenib	  (Cox	  and	  
Der	   2012).	   This	   inhibitor	   is	   more	   specific	   to	   B-­‐raf	   and	   has	   been	   used	   against	  
melanomas,	  and	  colon	  and	  thyroid	  cancers	  as	  a	  main	  chemotherapeutic	  drug.	  It	  
does	  however	  have	  side	  effects	  (Bollag	  et	  al	  2010,	  Heakal	  et	  al	  2011).	  Dabrafenib	  
is	  a	  successful	  inhibitor	  of	  Raf.	  In	  2013	  it	  went	  through	  phase	  II	  clinical	  trials	  and	  
now	   is	   the	   2nd	   FDA	   approved	   B-­‐raf	   inhibitor	   (Ascierto	   et	   al	   2013,	   Fiskus	   and	  
Mitsiades	   2016).	   Similarly	   to	   Ras	   inhibitors	   there	   is	   limited	   knowledge	   and	  
research	  surrounding	  their	  inhibition,	  as	  well	  as	  this	  cancer	  cells	  treated	  with	  B-­‐
Raf	  inhibitors	  are	  developing	  resistance.	  This	  remains	  an	  issue	  that	  is	  continuing	  
to	  be	  investigated	  (Shi	  et	  al	  2012,	  Solit	  and	  Rosen	  2014).	  	  
	  
MEK	  has	  been	  one	  of	  the	  more	  attractive	  proteins	  within	  the	  pathway	  to	  target	  
drugs	  against	  as	  it	  exhibits	  a	  low	  prevalence	  of	  mutations	  in	  comparison	  to	  Ras	  
and	  Raf	  (Marks	  et	  al	  2008).	  One	  of	  the	  first	  MEK-­‐targeted	  agents	  to	  enter	  clinical	  
trials	  was	   the	  drug	  CI-­‐1040.	   	  Though	   its’	  Phase	   I	   trials	  were	  halted	  due	   to	   low	  
bioavailability	  and	  Phase	   II	   trials	  were	   stopped	  due	   to	   its	   failure	   to	   show	  anti-­‐
tumour	  activity	  (LoRusso	  et	  al	  2005).	  However,	   this	  drug	  was	  then	  modified	  to	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create	  PDO325901,	  which	  has	   improved	   solubility	  but	   also	   it	   had	  adverse	   side	  
effects,	  which	  caused	  its	  trials	  to	  stop	  (Brown	  et	  al	  2007).	  A	  2nd	  generation	  MEK	  
inhibitor	   is	   Selumetinib.	  This	  agent	  has	  been	  shown	   to	  be	  highly	   selective,	   and	  
patients	  have	  had	  good	  toleration	   in	  Phase	   I	  studies,	  although,	   there	  are	   issues	  
with	  dosage	  and	  it	  can	  have	  severe	  side	  effects	  (Archibald	  et	  al	  2016,	  Temraz	  et	  
al	  2015).	  Alternatively	  in	  2013	  the	  MEK	  inhibitor,	  Trametinib	  became	  the	  first	  to	  
be	   approved	   by	   the	   United	   States	   FDA	   for	   treatment	   on	  metastatic	  melanoma	  
patients	   (Yao	   et	   al	   2015).	   This	   drug	   was	   utilised	   by	   Greger	   et	   al	   (2012)	   in	  
combination	  with	  a	  B-­‐raf	  inhibitor	  and	  together	  they	  effectively	  suppressed	  gene	  
expression	   and	   cell	   proliferation	   in	   melanoma	   cells.	   This	   drug	   binds	  
unphosphorylated	   MEK,	   thus	   preventing	   its	   activation	   and	   this	   remains	   a	  
promising	  drug	  for	  the	  treatment	  of	  cancers	  (Gilmartin	  et	  al	  2011).	  In	  addition	  to	  
this	   there	   are	   other	   drugs	   including	   PDO98059	   and	   UD126	   within	   preclinical	  
trials	   (Chappell	   et	   al	   2011).	   Thus	   far	   in	   cancer	   treatment	  MEK	   inhibitors	   have	  
been	  popular,	  what	  makes	  them	  not	  as	  desirable	  for	  the	  inhibition	  of	  the	  Ras,	  Raf,	  
MEK,	   ERK	   pathway	   is	   their	   dose-­‐limiting	   properties	   that	   lead	   to	   severe	   side	  
effects	  within	  patients	  (Marks	  et	  al	  2008).	  	  
	  
The	   final	   protein	   in	   the	   pathway	   to	   target	   is	   ERK.	   This	   protein,	   like	   MEK,	   is	  
another	  good	  target	  due	  to	  its	  effects	  on	  numerous	  proteins	  downstream	  that	  are	  
important	  with	   respect	   to	   cancer.	  There	  has	  however	  been	   limited	  progress	   in	  
development	   of	   selective	   inhibitors	   for	   ERK.	   That	   said,	   interest	   has	   recently	  
intensified,	  because	  of	  the	  rise	  of	  Raf	  and	  MEK	  inhibitor	  resistance.	  	  
	  
Ohori	  et	  al	  (2005)	  discovered	  the	  first	  selective	  inhibitor	  for	  ERK	  1/2.	  FR180204	  
acts	   as	   an	   ATP-­‐competitive	   inhibitor	   blocking	   access	   to	   the	   ATP	   binding	   site,	  
which	   is	   required	   for	   phosphate	   transfer,	   when	   ERK	   phosphorylates	   a	   target	  
protein	  (Figure	  1.4.).	  The	  inhibitor	  binds	  in	  a	  novel	  way	  to	  the	  unique	  residues	  of	  
ERK1/2	  but	  does	  not	  show	  selectivity	  between	  the	  two,	  which	  is	  desirable.	  It	  is	  
cell	  permeable	  and	  has	  been	  shown	  to	  inhibit	  the	  ERK	  signalling	  cascade	  (Dirican	  





Figure	  1.4	  ERK	  inhibiting	  compound	  FR180204	  and	  its'	  interactions	  with	  ERK’s	  
ATP	  binding	  pocket.	  Hydrogen	  bonds	  are	  observed	  between	  FR180204	  and	  ERK,	  
at	  residues	  Met	  108,	  Gln	  105	  and	  Asp	  106.	  Crystallographic	  image	  from	  Ohori	  et	  
al	  (2005),	  adapted	  in	  PyMOL. 
	  
	  
Ohori	  et	  al	  (2005)	  suggest	  that	  therapeutic	  applications	  such	  as	  the	  anti-­‐cancer	  
activity	  of	  MEK	  inhibitors	  may	  also	  be	  applicable	  to	  FR180204.	  There	  is	  evidence	  
suggesting	  that	  it	  could	  inhibit	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway	  and	  aid	  in	  cancer	  
treatment.	   FR180204	   was	   used	   in	   studies	   by	   Doghman	   and	   Lalli	   (2012)	   who	  
showed	   that	   the	  drug	   could	   act	   synergistically	  with	   a	  PI3K/mTOR	   inhibitor,	   to	  
achieve	   efficient	   inhibition	   of	   adrenocortical	   cancer	   cell	   proliferation.	   This	   is	   a	  
common	   suggestion	   in	   studies,	   which	   state	   that	   dual	   inhibition	   of	   signalling	  
pathways	  (particularly	   those	  that	  are	  overactive)	  within	  tumour	  cells	  may	  be	  a	  
more	   effective	   form	   of	   treatment	   against	   cancer	   growth	   (Chappell	   et	   al	   2011,	  
Dirican	   et	   al	   2015).	   This	   is	   applicable	   in	   cases	   of	   acquired-­‐cisplatin	   resistance	  
where	  by	   the	   inhibition	  of	  Ras,	  Raf,	  MEK,	  ERK	  signalling	  cascade	  as	  well	  as	   the	  
likes	   of	   the	   PI3K,	   Akt,	   mTOR	   pathway	   is	   desirable.	   This	   is	   because	   cross	   talk	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between	   the	   two	   pathways	   could	   limit	   efficacy	   of	   single	   drug	   treatment	   thus	  
eliminating	   both	   could	   be	   a	   more	   effective	   treatment	   strategy	   (Hanahan	   and	  
Weinberg	  2000,	  Mendoza	  et	  al	  2011).	  	  
	  
In	  addition	  to	  FR180204,	  there	  are	  several	  ERK	  inhibitors	  in	  development;	  these	  
include	  SCH772984	  (which	  is	  an	  ATP	  competitive	  inhibitor)	  that	  is	  derived	  from	  
small	  molecules	   that	   bind	   specifically	   to	   unphosphorylated	   ERK2	   (Morris	   et	   al	  
2013).	   As	   well	   as	   this	   there	   is	   BVD-­‐523	   and	   RG7842,	   which	   have	   recently	  
entered	  clinical	  trials	  but	  are	  not	  yet	  available	  (Samatar	  and	  Poulikakos	  2014).	  	  
 
1.8 The PI3K, Akt, mTOR signalling pathway 
 
Alongside	   the	   Ras,	   Raf,	   MEK,	   ERK	   pathway	   there	   are	   alternate	   signalling	  
cascades,	   thought	   to	  be	   involved	   in	   tumour	  progression	   and	  acquired	   cisplatin	  
resistance.	  One	  of	  these	  pathways	  is	  the	  PI3K,	  Akt,	  mTOR	  signalling	  cascade.	  This	  
pathway	   is	   promiscuous	   and	   works	   in	   parallel	   with	   the	   Ras,	   Raf,	   MEK,	   ERK	  
cascade	   contributing	   to	   the	   regulation	   of	   cell	   cycle	   progression	   and	   cellular	  
growth	   (Cheaib	   et	   al	   2015,	   Luo	   et	   al	   2003).	   It	   is	   also	   one	   the	  most	   frequently	  
deregulated	  signalling	  cascades	  in	  human	  malignancies	  (Dienstmann	  et	  al	  2014).	  	  
	  
The	  PI3K,	  Akt,	  mTOR	  signalling	  pathway,	  is	  mediated	  by	  a	  wide	  range	  of	  cellular	  
signal	   communicating	  molecules	   including	   hormones	   (such	   as	   insulin),	   growth	  
factors,	  nutrients	  (such	  as	  amino	  acids	  and	  glucose)	  and	  cellular	  stress	  (Kang	  et	  
al	   2012).	   It	   controls	   many	   intracellular	   processes	   including:	   proliferation,	  
differentiation	   and	   anti-­‐apoptotic	   signalling	   and	   the	   pathway	   comprises	   three	  
key	   proteins	   PI3K	   (phosphatidylinositol	   kinase),	   Akt	   (protein	   kinase	   B)	   and	  
mTOR	  (mammalian	  target	  of	  rapamycin)	  (Figure	  1.5).	  	  
	  
The	   PI3K	   pathway	   is	   initiated	   through	   a	   growth	   factor	   or	   ligand	   binding	   to	   a	  
receptor	   tyrosine	   kinase	   (RTK)(Eskander	   and	   Tewari	   2014).	   This	   receptor	   in	  
turn	  stimulates	  a	  GTPase	   i.e.	  Ras,	  which	  stimulates	  the	  activation	  of	  PI3K.	  PI3K	  
can	   be	   grouped	   into	   three	   different	   classes	   on	   the	   basis	   of	   properties	   such	   as	  
primary	  structure,	  regulation	  and	  function	  (Chang	  et	  al	  2015).	  Within	  PI3K	  class	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I	   there	  are	  4	  different	   isoforms	   (Wu	  and	  Hu	  2012).	  Each	  protein	  within	  class	   I	  
consists	   of	   regulatory	   (p85)	   and	   catalytic	   (p110α)	   subunits,	   producing	   a	  
heterodimer	  (Cantley	  2002,	  Cheaib	  et	  al	  2015).	  
	  
Direct	  binding	  of	   the	  p110α	  subunit	   to	  Ras	   initiates	  the	  activation	  of	  PI3K.	  p85	  
binds	   directly	   to	   phosphotyrosine	   residues	   on	   a	   RTK,	   which	   relieves	  
intermolecular	  inhibition	  of	  the	  p110α subunit	  by	  p85.	  PI3K	  is	  then	  localised	  to	  
the	  plasma	  membrane	  where	  its	  substrate	  phosphatidylinositol-­‐4,5-­‐biphosphate	  
resides	   (Duan	   et	   al	   2014).	   Here	   the	   conversion	   of	   phosphatidylinosital-­‐4,5-­‐	  
bisphosphate	  (PIP2)	  to	  phosphatidyinositol	  (3,	  4,	  5)-­‐triphosphate	  (PIP3)	  begins	  	  
(Cantley	  2002).	  
	  
Once	   PIP3	   accumulates	   at	   the	   plasma	   membrane,	   PI3K	   recruits	   a	   subset	   of	  
signalling	   proteins	   with	   pleckstrin	   homology	   (PH)	   domains	   to	   the	   membrane,	  
these	  include	  PDK1	  (phosphoinositide-­‐dependent	  kinase	  1)	  and	  Akt	  (Chang	  et	  al	  
2015).	   Akt	   then	   sub-­‐localises	   from	   the	   plasma	   membrane	   to	   sub-­‐cellular	  
compartments,	   where	   it	   phosphorylates	   substrates	   to	   exert	   distinct	   functions	  
(Duan	  et	  al	  2014).	  	  
	  
Akt	   belongs	   to	   the	   serine/threonine	   kinase	   family	   and	   is	   composed	   of	   three	  
structurally	  similar	  isoforms;	  Akt1,	  Akt2	  and	  Akt3,	  each	  of	  which	  has	  a	  different	  
role	  (Arboleda	  et	  al	  2003,	  Eskander	  and	  Tewari	  2014).	  Each	  isoform	  consists	  of	  
three	   domains,	   an	   N-­‐terminal	   PH	   domain,	   a	   central	   catalytic	   domain	   and	   a	   C-­‐
terminal	  extension	  with	  a	  hydrophobic	  motif	  (Chang	  et	  al	  2015).	  Akt’s	  plethora	  
of	   downstream	   effectors	   are	   involved	   in	   a	   variety	   of	   cellular	   processes	   that	  
include	   glucose	   metabolism,	   cell	   migration,	   transcription,	   proliferation	   and	  
apoptosis	   (Altomare	   et	   al	   2004).	   In	   addition,	  Akt	   is	   a	  well-­‐established	   survival	  
factor	   and	   works	   by	   exerting	   anti-­‐apoptotic	   effects	   through	   the	   prevention	   of	  
cytochrome	  c	  release	  and	  additionally	  inactivating	  pro-­‐apoptotic	  factors	  such	  as	  
BAD,	  pro-­‐caspase-­‐9,	  GSK3,	  p27	  and	  p70S6K	  (Altomare	  et	  al	  2004,	  Hu	  et	  al	  2002).	  	  
Akt	  promotes	  the	  transcription	  of	  anti-­‐apoptotic	  and	  proliferative	  genes	  through	  




Figure	  1.5	  Overview	  of	  the	  PI3K,	  Akt,	  mTOR	  signalling	  cascade. An	  extracellular	  
molecule	  (green)	  binds	  to	  its	  respective	  receptor	  (red)	  that	  spans	  the	  length	  of	  
the	  plasma	  membrane.	  The	  active	  receptor	  stimulates	  Ras’	  (blue)	  exchange	  of	  
GDP	  for	  GTP	  and	  once	  active	  Ras	  binds	  the	  p110	  subunit	  of	  PI3K	  (pink)	  to	  initiate	  
PI3K	  activation.	  PI3K	  controls	  the	  conversion	  of	  PIP2	  to	  PIP3.	  PTEN	  (aqua)	  can	  
revert	  the	  activity	  of	  PI3K,	  in	  turn	  inhibiting	  the	  pathways	  downstream	  actions.	  
PI3K	  facilitates	  the	  activation	  of	  PDK1	  (violet),	  which	  then	  activates	  Akt	  via	  
phosphorylation	  (orange).	  Akt	  has	  a	  number	  of	  downstream	  effectors	  itself	  
including	  the	  activation	  of	  TSC1	  (navy).	  TSC1	  activates	  mTORC1	  (magenta),	  
which	  goes	  on	  to	  initiate	  a	  plethora	  of	  downstream	  targets	  involved	  in	  cell	  
growth,	  migration	  and	  survival.  
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It’s	  involvement	  in	  various	  cellular	  processes	  means	  its	  regulation	  is	  of	  key	  
importance.	  This	  regulation	  is	  controlled	  by	  the	  phospholipid	  phosphatase	  
PTEN.	  PTEN	  serves	  at	  the	  molecular	  level	  to	  counteract	  the	  function	  of	  PI3K	  thus	  
deactivating	  Akt.	  This	  means	  it	  is	  a	  mediator	  of	  agonist-­‐induced	  apoptosis,	  
achieving	  this	  via	  up-­‐regulation	  of	  apoptotic	  machinery	  and	  down-­‐regulation	  of	  
anti-­‐apoptotic	  proteins	  (Chitcholtan	  et	  al	  2013,	  Hanahan	  and	  Weinberg	  2000). 
	  
One	  of	  Akt’s	  downstream	  effects,	  cell	  growth	  is	  for	  the	  most	  part	  controlled	  by	  its	  
effector	  mTOR	  (Duan	  et	  al	  2014).	  mTOR	  is	  a	  member	  of	  the	  phosphatidylinositol	  
3-­‐kinase-­‐related	  kinase	   (Pikk)	   family	  of	  proteins	  and	   is	   involved	   in	  an	  array	  of	  
cellular	   processes.	   It	   exists	   as	   two	   functional	   complexes	   called	   mTORC1	  
(complex	   1)	   and	  mTORC2	   (complex	   2),	  which	   localise	   to	   different	   sub-­‐cellular	  
compartments	  (Chang	  et	  al	  2015,	  Wu	  and	  Hu	  2012).	  mTOR	  is	  activated	  indirectly	  
by	  Akt	  through	  the	  inhibition	  of	  TSC2	  (tuberous	  sclerosis	  complex	  2),	  although	  it	  
is	   unknown	   whether	   this	   process	   alone	   is	   critical	   or	   sufficient	   for	   the	   full	  
activation	  of	  mTOR.	  It	  functions	  by	  integrating	  signals	  from	  upstream	  pathways	  
to	   up-­‐regulate	   the	   translation	   of	   genes	   involved	   in	   angiogenesis	   and	   cell-­‐cycle	  
progression,	   including	   VEGF,	   cyclin	   D1,	   and	   c-­‐myc	   as	   well	   as	   regulating	   cell	  
growth,	   proliferation,	   motility,	   survival,	   protein	   synthesis,	   autophagy	   and	  
transcription.	   In	   addition	   to	  motor’s	   downstream	  effects	   and	  potentials,	   it	   also	  
exerts	  positive	  feedback	  activity	  upon	  Akt	  (Cheaib	  et	  al	  2015).	  
 
There	  is	  accumulating	  evidence	  showing	  that	  this	  pathway	  is	  involved	  in	  tumour	  
growth,	   proliferation,	   metastasis	   and	   cisplatin	   resistance	   (Duan	   et	   al	   2014,	  
Mabuchi	   et	   al	   2015).	   Arboleda	   et	   al	   (2003)	   found	   an	   over-­‐expression	   of	   Akt2	  
with	  in	  vitro	  experiments	  on	  human	  ovarian	  cancer	  cells.	  This	  demonstrated	  that	  
increased	   cancer	   cell	   invasion	   and	   metastasis	   was	   associated	   with	   over-­‐
expression	  of	  Akt2	  and	  the	  PI3K	  pathway.	  The	  cause	  behind	  Akt	  over	  expression	  
can	  be	  linked	  to	  PI3KCA	  mutations	  commonly	  found	  in	  ovarian	  and	  endometrial	  
tumour	   cells	   (Bjornsti	   and	   Houghton	   2004,	   Hanrahan	   et	   al	   2012).	   This	   gene	  
encodes	   the	   p100α	   subunit	   of	   PI3K	   and	   is	   found	   in	   more	   than	   30%	   of	   solid	  
tumours	   (Wu	   and	   Hu	   2012).	   It	   is	   thought	   this	   mutation	   causes	   PI3K	   to	   be	  
constitutively	  active	   thus	   influencing	  the	  activation	  of	   its	  downstream	  effectors	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including	  Akt.	   In	  addition,	  PTEN	  mutations	  are	  commonly	  found	  in	  ovarian	  and	  
endometrial	   cancers	   and	   these	   mutations	   can	   also	   lead	   to	   uncontrollable	   Akt	  
expression	   (Hanahan	   and	   Weinberg	   2000).	   This	   is	   due	   to	   the	   mutant	   PTEN	  
protein	  lacking	  the	  ability	  to	  bind	  PI3K	  and	  regulate	  its	  activity	  thus	  Akt	  becomes	  
hyper-­‐activated	  (Bjornsti	  and	  Houghton	  2004,	  Chitcholtan	  et	  al	  2013).	  	  
	  
Akt2	   over	   expression	   promotes	   survival	   through	   BAD	   (Bcl-­‐2	   associated	   death	  
promoter),	  which	  inactivates	  apoptosis	  (Hu	  et	  al	  2002).	  Ovarian	  cancer	  cell	  lines	  
with	  constitutively	  active	  Akt1	  or	  Akt2	  have	  been	  found	  to	  be	  highly	  resistant	  to	  
paclitaxel	   (a	   platinum	   based	   drug)	   (Altomare	   et	   al	   2004).	   Other	   studies	   have	  
demonstrated	   that	   Akt	   directly	   phosphorylates	   XIAP	   (X-­‐linked	   inhibitor	   of	  
apoptosis	   protein),	   leading	   to	   inhibition	   of	   cisplatin-­‐induced	   ubiquitation	   and	  
degradation.	   This	   protects	   tumour	   cells	   from	   drug-­‐induced	   apoptosis.	  
Furthermore,	   the	   presence	   of	   Akt	   has	   been	   shown	   in	   tumour	   cells	   throughout	  
endometrial	   cancer	   progression,	   this	   suggests	   Akt	   may	   have	   a	   role	   in	   chemo-­‐
protection	  making	   both	   this	   pathway	   and	   protein	   attractive	   targets	   (Basu	   and	  
Krishnamurthy	  2010,	  Gagnon	  et	  al	  2004,	  Yang	  et	  al	  2004).	  	  
	  
Girouard	   et	   al	   (2013)	   showed	   that	   simultaneous	   down	   regulation	   of	   Akt1	   and	  
Akt2	   restored	   cisplatin-­‐induced	   apoptosis	   in	   resistant	   endometrial	   cells.	   This	  
demonstrates	   that	   the	   inhibition	  of	   this	  pathway	  could	  be	  used	   in	  combination	  
with	  chemotherapeutic	  drugs	  like	  cisplatin	  to	  restore	  the	  platinum-­‐sensitivity	  to	  
tumour	  cells	  (Altomare	  et	  al	  2004,	  Cheaib	  et	  al	  2015,	  Kang	  et	  al	  2012,	  Luo	  et	  al	  
2003).	  	  
 
1.9 PI3K, Akt, mTOR pathway inhibitors  
 
It	   has	   been	   suggested	   that	   in	   order	   to	   inhibit	   a	   particular	   protein	   within	   a	  
signalling	   pathway,	   and	   at	   the	   same	   time	   illicit	   a	   strong	   tumour	   response	   or	  
initiate	   tumour	   regression,	   combinatory	   therapy	   is	   advantageous	   (Hanrahan	  et	  
al	   2012,	   Mabuchi	   et	   al	   2015).	   Such	   dual	   inhibition	   therapy	   is	   becoming	   an	  
increasingly	   popular	   approach	   when	   investigating	   growth	   and	   signalling	  
pathways.	  This	  is	  because	  single	  inhibitors	  have	  limited	  efficacy	  due	  to	  potential	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feedback	  loops	  that	  can	  reduce	  any	  inhibitory	  effects,	  therefore	  targeting	  several	  
pathways	  is	  an	  effective	  option	  (Chang	  et	  al	  2015,	  Engelman	  2009).	  Combination	  
therapies	   are	   needed	   as	   they	   both	   enhance	   initial	   response	   and	   reduce	  
subsequent	   onset	   of	   drug	   resistance	   (Cox	   and	   Der	   2012).	   This	   suggests	   that	  
inhibiting	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway	  and	  the	  PI3K,	  Akt,	  mTOR	  pathway	  to	  
reduce	  their	  potential	  over-­‐activity	  within	  ovarian	  and	  endometrial	  cancers	  may	  
be	  an	  effective	  approach.	  As	  previously	  discussed	  ERK	  is	  an	  attractive	  target	  for	  
Ras	   pathway	   inhibition	   leaving	   the	   question	   of	   what	   protein	   is	   the	   most	  
appropriate	  to	  target	  in	  the	  PI3K	  pathway.	  	  
	  
The	   first	   target	   is	   PI3K,	   and	   this	   has	   been	   suggested	   to	   be	   the	   most	   direct	  
approach	   for	   PI3K	   pathway	   inhibition	   (Hu	   et	   al	   2002).	   Two	   of	   the	   first	   PI3K	  
prototype	  inhibitors	  developed	  were	  LY294002	  and	  wortmannin.	  Both	  of	  these	  
target	  the	  catalytic	  site	  of	  the	  p110	  α	  subunit	  and	  have	  become	  invaluable	  tools	  
in	  elucidating	  the	  roles	  of	  the	  PI3K	  protein	  (Walker	  et	  al	  2000,	  Wu	  and	  Hu	  2012).	  
Wortmannin	   is	   a	  microbial	   product	   and	   a	  potent	   irreversible	   inhibitor	   of	   PI3K	  
but	  is	  difficult	  to	  work	  with	  due	  to	  problems	  with	  its	  stability,	  solubility	  and	  toxic	  
side	  effects	  (Arcaro	  and	  Wymann	  1993,	  Chang	  et	  al	  2015,	  Dan	  et	  al	  2009,	  Powis	  
et	  al	  1994,	  Yaguchi	  et	  al	  2006).	  The	  first	  study	  involving	  wortmannin	  was	  shown	  
to	  inhibit	  phagocytosis	  induced	  respiratory	  bursts,	  and	  it	  was	  elucidated	  this	  was	  
due	   to	   specific	   PI3K	   inhibition	   (Baggiolini	   et	   al	   1987).	   Recently	   a	   newer	  
compound	   has	   been	   developed	   based	   on	   the	   structure	   of	   wortmannin,	   this	   is	  
called	  ZSTK474.	   It	  has	  a	  20	   fold	  greater	  activity	  and	  has	  been	  showing	  efficacy	  
within	   clinical	   trials	   (Barollo	   et	   al	   2014,	   Kong	   and	   Yamori	   2007,	   Yaguchi	   et	   al	  
2006).	  
	  
	  LY294002	  was	  the	  first	  known	  synthetic	  inhibitor	  of	  PI3K,	  with	  a	  structure	  that	  
was	   based	   on	   quercetin	   (a	   naturally	   occurring	   bioflavanoid).	   LY294002	   has	   a	  
much	  lower	  potency	  than	  wortmannin	  but	  its	  stability	  is	  far	  superior	  as	  well	  as	  
reversible,	  allowing	  it	  to	  become	  more	  widely	  used	  in	  studies	  on	  PI3K	  (Guo	  et	  al	  
2014,	  Wu	  and	  Hu	  2012).	  LY294002	  acts	  as	  a	  competitive	  and	  reversible	  inhibitor	  
at	  PI3K’s	  ATP	  binding	  site	  and	  selectively	  inhibits	  the	  PI3K-­‐ATP	  nexus	  (Badinloo	  
and	   Esmaeili-­‐Mahani	   2014,	   Guo	   et	   al	   2014).	   Another	   specific-­‐PI3K	   inhibitor	   is	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NVP-­‐BKM120,	  within	  preclinical	  studies;	  this	  agent	  has	  been	  shown	  to	  suppress	  
proliferation	  and	  induces	  apoptosis.	  	  
	  
With	   respect	   to	   its	   effects	   on	   cancer	   cells,	   LY294002	   has	   featured	   in	   many	  
studies.	   Hu	   et	   al	   (2002)	   demonstrate	   that	   LY294002	   has	   the	   ability	   to	   halt	  
tumour	  growth	   in	  vivo	   in	  a	  mouse	  ovarian	  cancer	  model.	  Altomare	  et	  al	  (2004)	  
used	   LY294002	   alongside	   paclitaxel	  within	   in	   vitro	   and	   in	   vivo	  ovarian	   cancer.	  
They	   found	   reduction	   in	   tumour	   growth	   and	   dissemination	   in	   combination	  
treatments	  compared	  to	  single	  treatments	  of	  the	  individual	  drugs.	  Similarly,	  Luo	  
et	  al	  (2013)	  found	  LY294002	  to	  reduce	  protein	  expression	  of	  Akt1	  and	  pAkt1	  in	  
spheroid	  cells	  and	  in	  combination	  with	  paclitaxel	  the	  cells	  were	  re-­‐sensitised	  to	  





Figure	  1.6	  PI3K	  inhibiting	  compound	  LY294002	  and	  its'	  interactions	  with	  PI3K’s	  
ATP	   binding	   pocket.	   A	   hydrogen	   bond	   with	   Val	   882	   is	   shown	   as	   the	   primary	  
interaction	  between	  LY294002	  and	  PI3K.	  Crystallographic	  image	  from	  Walker	  et	  
al	  (2000),	  adapted	  in	  PyMOL. 
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With	  respect	  to	  the	  use	  of	  LY294002,	  in	  cisplatin-­‐based	  studies,	  Liu	  et	  al	  (2015)	  
showed	   after	   cisplatin	   treatment,	   the	   PI3K	   pathway	   was	   activated	   and	   the	  
expression	   of	   XIAP	  was	   enhanced,	  which	   restrained	   cell	   apoptosis	   and	   lead	   to	  
further	   cisplatin	   resistance.	   However,	   when	   treated	   with	   LY294002	   and	  
cisplatin,	  the	  expression	  of	  pAkt	  decreased	  and	  the	  elevated	  expression	  of	  XIAP	  
induced	   by	   cisplatin	   was	   inhibited.	   This	   encourages	   the	   use	   of	   LY294002	   in	  
combination	   with	   cisplatin	   and	   shows	   promise	   for	   its	   application	   in	   cancer	  
treatment.	  
	  
There	   is	   still	   uncertainty	   in	   whether	   specific	   or	   broad	   PI3K	   inhibitors	   are	  
clinically	  more	  effective	  and	  further	  research	  is	  required	  to	  clarify	  this.	  There	  is	  
likely	   to	   be	   additional	   toxicity	   caused	   by	   the	   complete	   inhibition	   of	   all	   PI3K	  
isoforms	  (Engelman	  2009).	  Unfortunately,	  PI3K	  inhibition	  does	  come	  with	  some	  
adverse	   effects	   resulting	   from	   the	   inhibition	   of	   PI3K	   dependant	   cellular	  
processes.	   One	   of	   which	   is	   glucose	   homeostasis,	   and	   PI3K	   inhibition	   disrupts	  
insulin’s	  effects	  on	  metabolism,	  which	  are	  mediated	  through	  this	  pathway	  (Hu	  et	  
al	  2002).	  	  
	  
Another	   inhibition	  option	  that	  has	  been	  was	  suggested	   in	  several	  studies	   is	   the	  
use	  of	  a	  dual	  PI3K/mTOR	  inhibitor.	  Both	  PI3K	  and	  mTOR	  are	  apart	  of	  the	  PI3K-­‐
related	  kinase	  super	  family	  and	  there	  are	  inhibitory	  compounds	  that	  can	  target	  
both	   proteins.	   These	   inhibitors	   target	   the	   proteins	   both	   upstream	   and	  
downstream	   of	   Akt.	   Thus	   they	   avoid	   activation	   of	   Akt	   by	   the	  mTOR-­‐S6K-­‐IRS1	  
negative	  feedback	  loop	  (Chappell	  et	  al	  2011,	  Mazzoletti	  et	  al	  2011).	  An	  example	  
of	   this	   type	   of	   inhibitor	   is	   NVP-­‐BEZ235	   (Schnell	   et	   al	   2008).	   This	   inhibitor	  
exhibited	  reduced	  tumour	  growth	  in	  mouse	  models	  (Serra	  et	  al	  2008).	  The	  most	  
recent	  studies	  of	   this	   inhibitor	  show	   it	  within	  preclinical	   trials	   slowing	   tumour	  
progression	   as	   well	   as	   working	   in	   combination	   with	   cisplatin	   and	   effectively	  
inducing	   apoptosis	   (Gobin	   et	   al	   2014,	   Yang	   et	   al	   2013).	   These	   inhibitors	  may	  
represent	  an	  option	  as	   they	  provide	  maximal	   therapeutic	  efficacy,	  especially	  as	  
mTOR	  is	  a	  positive	  regulator	  of	  Akt	  (Roper	  et	  al	  2011).	  Although	  Dienstmann	  et	  
al	   (2014)	   	   suggest	   that	   broad-­‐PI3K	   inhibitors	   are	  better	   suited	   to	   combination	  
therapy	  rather	  than	  PI3K-­‐mTOR	  ones.	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The	  next	  option	  would	  be	  to	  inhibit	  Akt	  and	  advances	  in	  drug	  design	  have	  seen	  
the	   development	   of	  more	   potent	   Akt	   inhibitors.	   Currently	   the	  most	   promising	  
inhibitor	   is	   perifosine,	   which	   is	   in	   phase	   III	   trials	   and	   has	   promising	   use	   in	  
combination	   with	   drugs	   such	   as	   sorafenib	   and	   effectively	   inhibits	   Akt	   (Carlo-­‐
Stella	  et	  al	  2010,	  Gills	  and	  Dennis	  2009,	  Guidetti	  et	  al	  2014,	  Hennessy	  et	  al	  2007).	  
Another	   highly	   studied	   Akt	   inhibitor	   is	   GSK690693,	   is	   a	   selective	   broad-­‐Akt	  
inhibitor.	  It	  is	  in	  clinical	  development	  and	  has	  shown	  promising	  results	  inducing	  
apoptosis	  in	  combination	  treatments	  on	  colon	  cancer	  cells	  (Heerding	  et	  al	  2008,	  
Pal	   et	   al	   2010).	   Unfortunately	   so	   far	   these	   second	   generation	   inhibitors	   have	  
shown	  more	  anti-­‐proliferative	  effects	  rather	  than	  anti-­‐tumour	  effects	  but	  further	  
development	  may	  improve	  this	  for	  future	  studies.	  	  
	  
Investigations	   of	   mTOR	   inhibition	   began	   with	   the	   discovery	   of	   rapamycin	   or	  
serolimus,	   the	   product	   of	   a	   bacterium.	   First	   generation	  mTOR	   inhibitors	  were	  
derivatives	  of	  rapamycin	  and	  called	  rapalogs	  (Zaytseva	  et	  al	  2012).	  These	  have	  
been	   proven	   to	   be	   effective	   in	   some	   trials	   and	   examples	   of	   these	   are	  
temserolimus	   and	   everolimus	   (Hudes	   et	   al	   2007).	   Unfortunately,	   the	   positive	  
effects	  of	  these	  inhibitors	  were	  limited	  to	  rare	  cancers	  and	  they	  did	  not	  exhibit	  
robust,	  broad	  anti-­‐cancer	  effects.	  This	   is	  due	  to	   the	   inhibitors	   failing	  to	  repress	  
mTOR's	   negative	   feedback	   loop.	   	   Second	   generation	   mTOR	   inhibitors	   are	  
commonly	  called	  mTORC1/mTORC2	  dual	  inhibitors.	  These	  compete	  with	  ATP	  at	  
the	   catalytic	   site	   of	   mTOR	   and	   unlike	   first	   generation	   inhibitors,	   block	   the	  
negative	   feedback	   loop	   preventing	   the	   activation	   of	   PI3K	   and	   Akt.	   These	  
inhibitors	  shown	  limited	  success	  with	  KRAS	  driven	  tumours,	  thus	  it	  is	  advised	  to	  
use	   these	   in	   combination	  with	   other	   inhibitors	   (Falcon	   et	   al	   2011,	   Gupta	   et	   al	  
2012).	  	  
	  
From	   the	   studies	   described	   above	   the	   potential	   efficacy	   of	   LY294002	   when	  
combined	  with	  cisplatin,	  towards	  ovarian	  and	  endometrial	  cancers	  warrants	  the	  
further	  investigation	  of	  this	  drug,	  In	  combination	  with	  an	  ERK	  inhibitor	  such	  as	  
FR180204	   these	   agents	   have	   the	   potential	   to	   create	   a	   novel	   treatment	   for	  
cancers	  that	  show	  resistance	  to	  chemotherapeutic	  agents	  such	  as	  cisplatin.	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1.10 Hypotheses and Aims  
 
The	   overall	   aim	   for	   this	   project	   is	   to	   investigate	   the	   potential	   of	   inhibitors	  
FR180204	   and	   LY294002	   in	   re-­‐sensitising	   OVCAR-­‐5	   and	   Hec-­‐1A	   cell	   lines	   to	  
cisplatin	  treatment	  as	  well	  as	  the	  opportunity	  of	  developing	  a	  novel	  combination	  
therapy	  that	  is	  effective	  against	  cisplatin	  resistant	  cancers.	  
	  
Objectives:	  
1. To	   investigate	   FR180204	   and	   LY294002’s	   efficacy	   individually	   in	  
preventing	  cellular	  growth	  and	  proliferation.	  
	  
2. To	  investigative	  FR180204	  and	  LY294002’s	  efficacy	  in	  preventing	  cellular	  
growth	   and	   proliferation	   in	   combination	   with	   cisplatin	   to	   re-­‐sensitise	  
resistant	  cell	  lines.	  	  
	  
3. To	  investigate	  the	  expression	  of	  cell	  cycle,	  signalling	  and	  growth	  pathway	  
proteins	  in	  both	  OVCAR-­‐5	  and	  Hec-­‐1A	  cell	  lines.	  Justifying	  the	  rationale	  in	  
targeting	  specific	  signalling	  proteins,	  ERK	  and	  Akt.	  	  
	  
4. To	  investigate	  the	  expression	  of	  cell	  cycle,	  signalling	  and	  growth	  pathway	  
proteins	   in	   both	   OVCAR-­‐5	   and	   Hec-­‐1A	   after	   treatment	   with	   FR180204,	  
LY294002	  and	   cisplatin.	  This	  will	   justify	   the	  use	  of	   these	   inhibitors	   and	  
what	   effects	   they	  may	   have	   on	   the	   cells.	   As	  well	   as	   the	   efficacy	   of	   dual	  
inhibition	  in	  combination	  with	  cisplatin	  as	  a	  novel	  therapy.	  	  
	  
It	   is	   hypothesized	   that	   upon	   addition	   of	   FR180204,	   LY294002	   and	   cisplatin	   to	  
OVCAR-­‐5	   and	   Hec-­‐A1	   cell	   lines,	   a	   reduction	   of	   cell	   growth,	   proliferation	   and	  
protein	   expression	   within	   both	   cultures	   will	   occur.	   Ultimately	   the	   addition	   of	  
inhibitors	  FR180204	  and	  LY294002	  will	  re-­‐sensitise	  the	  cancer	  cells	  to	  cisplatin,	  
thus	   producing	   a	   novel	   targeted	   combination	   therapy.	   This	   research	   has	   the	  
potential	  to	  be	  incorporated	  into	  current	  cancer	  treatments	  in	  order	  to	  provide	  
additional	  treatment	  strategies.	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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Chemicals and Cell Lines 
 
Unless	  stated	  otherwise,	  all	  chemicals	  and	  solutions	  were	  purchased	  from	  Sigma-­‐
Aldrich	   (Auckland,	   New	   Zealand),	   and	   all	   buffers	   were	   prepared	   with	   MilliQ	  
water.	  The	  human	  cancer	  cell	  lines	  used	  (ovarian	  adenocarcinoma,	  OVCAR-­‐5	  and	  
endometrial	   adenocarcinoma,	  Hec-­‐1A)	  were	  provided	  by	  Dr	  Kenny	  Chitcholtan	  
(Department	  of	  Obstetrics	  and	  Gynaecology,	  University	  of	  Otago,	  Christchurch).	  
Both	  cell	   lines	  were	  maintained	  in	  Dulbecco’s	  Modified	  Eagle	  Medium/Nutrient	  
Mixture	  F-­‐12	  (DMEM/F-­‐12	  catalogue	  number	  12500-­‐062)	  base	  media	  (GIBCO®,	  
Invitrogen,	  New	  Zealand),	  PenStrep	  antibiotics	  (GIBCO,	  Invitrogen,	  New	  Zealand)	  
at	   a	   concentration	   of	   100	   units/mL	   penicillin	   and	   100	   µg/mL	   streptomycin,	   2	  
mM	   glutaMAXTM	   (GIBCO®,	   Invitrogen,	   New	   Zealand),	   and	   2µg/mL	   Fungizone®	  
(Invitrogen,	  New	  Zealand).	  Henceforth,	  this	  supplemented	  DMEM/F-­‐12	  media	  is	  
referred	  to	  as	  the	  working	  media.	  	  
 
2.2 2D Cell Culture  
 
The	   following	   procedures	   were	   completed	   under	   sterile	   conditions	   in	   a	   cell	  
culture	   laminar	   flow	   cabinet.	   Both	   cell	   lines	   were	   continuously	   maintained	   at	  
37°C	   in	   a	   humidified	   5%	   CO2	   incubator	   in	   culturing	   flasks	   containing	  working	  
media.	   	   The	   culture	  medium	  was	   replaced	   every	   two	   days	  with	   fresh	  working	  
media	   until	   the	   cells	   reached	   near	   confluence,	   as	   assessed	   using	   a	   light	  
microscope.	  At	  this	  stage	  the	  cells	  were	  sub-­‐cultured.	  The	  sub-­‐culturing	  protocol	  
involved	   discarding	   the	   media,	   rinsing	   the	   flask	   with	   1x	   sterile	   phosphate	  
buffered	  saline	  (PBS)	  pH	  7.4,	  and	  adding	  1x	  trypsin-­‐ethylenediaminetetraacetic	  
acid	   (trypsin-­‐EDTA).	   Flasks	   were	   incubated	   with	   trypsin-­‐EDTA	   for	   20-­‐30	  
minutes	   to	   remove	   the	   adhered	   cells	   from	   the	   flask	   bottom.	   Cells	   were	   then	  
pelleted	   by	   centrifugation	   at	   1500	   rpm	   for	   five	   minutes	   and	   the	   supernatant	  
discarded.	   The	   remaining	   pellet	   was	   re-­‐suspended	   in	   working	   media.	  
Resuspended	  cells	  were	  diluted	  two	  times	  with	  1x	  PBS,	  and	  a	  cell	  count	  carried	  
out	   using	   a	   haemocytometer.	   The	   average	   cell	   count	  was	   used	   to	   calculate	   the	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volume	  of	  cells	  required	  for	  2x105	  cells	  per	  well.	  This	  volume	  was	  then	  added	  to	  
each	  well	   in	   a	   12-­‐well	   cell	   culture	   plate,	   and	  working	  media	   added	   to	  make	   a	  
total	   volume	   of	   1000	   µl	   per	   well.	   Approximately	   500	   µl	   of	   the	   remaining	   cell	  
suspension	  was	  added	  to	  a	  new	  culture	  flask	  that	  contained	  fresh	  working	  media	  
for	  maintenance	  of	  the	  cell	  line.	  	  
2.3 Drug Treatment 
 
After	  two	  days	  of	  cell	  growth	  in	  12-­‐well	  plates	  drug	  treatments	  were	  added.	  Cells	  
were	   treated	   singly	   with	   the	   cytotoxic	   drug	   cisplatin	   (cis-­‐
diamminedichloroplatinum	  (II)),	  the	  ERK	  inhibiting	  compound	  FR180204	  or	  the	  
PI3K	  inhibiting	  compound	  LY294002.	  Stock	  solutions	  of	  16.6	  mM	  cisplatin,	   	  1.6	  
mM	   FR180204	   and	   16.6	   mM	   LY294002	   were	   prepared	   in	   100%	   dimethyl	  
sulphoxide	  (DMSO).	  	  Three	  concentrations	  of	  LY294002	  (2	  µM,	  4	  µM	  and	  8	  µM)	  
and	  three	  concentrations	  of	  cisplatin	  (5	  µM,	  10	  µM	  and	  15	  µM)	  were	  tested.	  For	  
the	   control,	   DMSO	   was	   added	   at	   a	   volume	   equal	   to	   that	   which	   the	   cells	   are	  
exposed	  to	  with	  the	  highest	  concentration	  of	  drug	  treatment	  (0.01%(v/v)	  in	  the	  
cisplatin	   treatment	   and	   0.005%(v/v)	   in	   the	   LY294002	   treatment).	   In	   the	  
combination	  experiments,	  four	  different	  combinations	  of	  drugs	  were	  used	  8	  µM	  
FR180204	   and	   8	   µM	   LY294002	   combination,	   8	   µM	   FR180204	   and	   10	   µM	  
cisplatin	   combination,	  8	  µM	  LY294002	  and	  10	  µM	  cisplatin	   combination	  and	  8	  
µM	   FR180204,	   8	   µM	   LY294002	   and	   10	   µM	   cisplatin	   combination.	   The	  
combination	   treatment	   control	   contained	   0.07	   %	   (v/v)	   DMSO.	   In	   each	  
experiment	   there	   were	   three	   replicate	   wells	   for	   each	   treatment.	   Treated	   cells	  
were	   returned	   to	   the	   incubator	   for	   either	  24	  or	  48	  hours	  before	  analysing	   cell	  
metabolism	  and	  growth	  activity.	  	  
2.5 Alamar Blue Assay 
 
Cellular	  metabolism	   after	   drug	   treatment	   was	   assessed	   by	   addition	   of	   Alamar	  
Blue	   (Invitrogen,	  New	  Zealand)	   after	   either	   24	   or	   48	  hours	   of	   exposure	   to	   the	  
drugs.	  Alamar	  Blue	  (resazurin)	  is	  a	  blue	  dye	  that	  is	  reduced	  to	  a	  pink	  compound	  
(resorufin)	  in	  the	  presence	  of	  respiring	  cells	  due	  to	  mitochondrial	  activity.	  Half	  of	  
the	  media	  was	  removed	  from	  each	  well	  before	  adding	  Alamar	  Blue,	  followed	  by	  
an	  incubation	  period	  of	  four	  hours.	  After	  this	  duration,	  solution	  (not	  cells)	  from	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each	  well	  was	  loaded	  onto	  a	  96-­‐well	  plate.	  A	  change	  of	  colour	  from	  blue	  to	  pink	  
was	  measured	  by	  absorbance	  at	  570	  nm	  and	  600	  nm	  using	  a	  microplate	  reader	  
(SpectraMax®	  M5,	  Molecular	  Devices).	  The	  difference	  between	  the	  absorbance	  at	  
570	  nm	  and	  600	  nm	  was	  used	  as	  a	  measure	  of	  the	  cells	  metabolic	  activity.	  	  
2.6 Crystal Violet Assay  
 
Following	   the	   Alamar	   Blue	   assay,	   cell	   numbers	  were	   indirectly	   determined	   by	  
measuring	   cellular	   DNA	   content	   using	   crystal	   violet	   staining.	   Crystal	   violet	  
(tris(4-­‐(dimethylamino)phenyl)methylium	  chloride)	  is	  a	  purple	  dye	  that	  binds	  to	  
DNA.	   Its	   absorbance	  at	  570	  nm	  enables	   a	  quantification	  of	   the	  amount	  of	  DNA	  
within	  a	  sample,	  which	  is	  proportional	  to	  the	  total	  cell	  number.	  The	  Alamar	  Blue	  
solution	  was	  discarded	  and	  1x	  PBS	  pH	  7.4	   added	   to	   each	  well	   to	   rinse	  out	   the	  
Alamar	  Blue.	  Cells	  were	   then	  detached	   from	  the	  bottom	  of	   the	  wells	  by	  adding	  
10x	  trypsin-­‐EDTA	  and	  incubating	  at	  37°C	  for	  10-­‐20	  minutes.	  Cells	  were	  pelleted	  
by	   centrifugation	   at	   2500	   rpm	   for	   five	   minutes	   and	   the	   PBS	   supernatant	  
discarded.	  2mg/mL	  crystal	  violet	  in	  2%	  (v/v)	  ethanol	  in	  MilliQ	  water	  was	  added	  
and	  incubated	  at	  room	  temperature	  for	  30	  minutes.	  The	  cells	  were	  washed	  with	  
MilliQ	  water	   to	   remove	   non	   DNA-­‐bound	   crystal	   violet	   dye.	  Washed	   cells	  were	  
pelleted	   by	   centrifugation	   at	   2000	   rpm	   for	   five	   minutes	   and	   the	   supernatant	  
discarded.	  This	  washing	  step	  was	  repeated	  four	  times	  before	  lysing	  cells	  with	  2%	  
(w/v)	   sodium	   dodecyl	   sulphate	   (SDS).	   The	   lysed	   cell	   solutions	   from	   each	  well	  
were	  then	  loaded	  onto	  a	  96-­‐well	  plate	  and	  the	  optical	  density	  at	  560	  nm	  (OD560)	  
was	  measured	  using	  the	  microplate	  reader.	  	  
 
2.7 3D Cell Culture  
 
Alternatively	  to	  2D	  cell	  culture,	  the	  majority	  of	  experiments	  were	  done	  in	  3D	  cell	  
culture	  conditions.	  This	  method	  uses	  culture	  plates	  coated	  with	  a	  polymer	   that	  
prevents	  cells	  from	  adhering	  to	  the	  plates	  causes	  the	  cells	  to	  cluster	  together	  and	  
form	   3D	   spheroids.	   This	   3D	   model	   is	   likely	   to	   be	   a	   more	   appropriate	  
representation	   of	   in	   vivo	   solid	   tumours.	   12-­‐well	   plates	   were	   pre-­‐coated	   with	  
poly-­‐hydroxyethylmethacrylate	   (poly-­‐HEMA).	   Poly-­‐HEMA	   was	   added	   to	   95%	  
ethanol	  at	  a	  concentration	  of	  12mg/mL	  and	  dissolved	  by	  heating	  at	  70°C.	  Once	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completely	  dissolved,	  500	  µL	  per	  well	  of	  poly-­‐HEMA	  solution	  was	  added	  per	  well	  
to	  the	  12-­‐well	  plates,	  which	  were	  then	  incubated	  overnight	  on	  an	  orbital	  shaker	  
at	  37°C.	  Before	  adding	  cells,	  the	  coated	  wells	  were	  washed	  with	  1x	  PBS	  pH	  7.4.	  
The	   remaining	   procedures	  were	   similar	   to	   that	   of	   the	   2D	   cell	   cultures,	   except	  
with	   minor	   modifications.	   Whenever	   drawing	   up	   media	   from	   the	   wells,	   the	  
plates	  were	   left	   to	   rest	  at	  an	  angle	   for	  approximately	   five	  minutes	   to	  allow	  the	  
spheroids	   to	   settle.	   For	   the	   crystal	   violet	   assay,	   the	   remaining	   Alamar	   Blue	  
solution	  and	  cells	  were	  transferred	  to	  centrifuge	  tubes	  with	  3	  mL	  1x	  PBS	  pH	  7.4	  
as	  a	  wash	  for	  the	  wells.	  The	  tubes	  were	  spun	  at	  2000	  rpm	  for	  five	  minutes	  and	  
the	   Alamar	   Blue-­‐containing	   supernatant	   discarded.	   	   Cells	   were	   then	   digested	  
with	   10x	   trypsin-­‐EDTA	   and	   incubated	   at	   37°C	   for	   10-­‐20	  minutes.	   Tubes	  were	  
spun	  again	   for	   five	  minutes	  at	  2000	  rpm	  and	  the	  supernatant	  discarded	  before	  
adding	   crystal	   violet	   to	   each	   tube.	   The	   remainder	   of	   the	   protocol	   was	   as	  
described	  before	  for	  the	  2D	  cell	  cultures.	  	  
 
2.8 Western Blot Analysis  
 
Cells	  were	  lysed	  by	  adding	  200	  µL	  of	  0.1%	  SDS	  to12-­‐well	  plates	  and	  incubating	  
on	  ice	  for	  20	  minutes.	  The	  cell	  lysates	  were	  then	  collected.	  
	  
Sodium	   dodecyl	   sulphate	   poly-­‐acrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	  was	  
used	   to	   separate	   the	   cell	   lysates.	   The	   protein	   concentration	   of	   each	   cell	   lysate	  
was	   determined	   using	   Micro-­‐BCATM	   Protein	   Assay	   Kit	   (Pierce,	   Thermo	   Fisher	  
Scientific,	  Rockford,	   IL,	  USA)	  and	  this	  concentration	  was	  used	  to	  determine	   the	  
volume	   of	   each	   cell	   lysate	   that	  was	   required	   to	   load	   10	   µg	   of	   protein	   per	   cell	  
lysate	  onto	  the	  gel	  (see	  Appendix).	  To	  prepare	  them	  for	  loading	  onto	  the	  gel,	  the	  
cell	  lysates	  were	  mixed	  with	  sample	  buffer	  (20%	  (v/v)	  bromophenol	  blue,	  50%	  
(v/v)	  glycerol,	  in	  Tris-­‐HCl	  pH	  6.8)	  and	  heated	  at	  90°C	  for	  10	  minutes,	  followed	  by	  
centrifugation	   for	   seven	  minutes	   at	   12,000	   rpm.	   Cell	   lysates	  were	   loaded	   onto	  
Bolt™	   4-­‐12%	  Bis,-­‐Tris	   Plus	   gels	   (Invitrogen,	   New	   Zealand)	   	   and	   the	   SDS-­‐PAGE	  
was	   run	   for	   approximately	   120	   minutes	   at	   120	   Volts	   using	   Bolt™	   MES	   SDS	  
Running	   Buffer	   (Invitrogen,	   New	   Zealand).	   MagicMarkTM	   Western	   Protein	  
Standard	  (Invitrogen,	  New	  Zealand)	  and	  Precision	  Plus	  ProteinTM	  standard	  (BIO-­‐
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RAD,	  Hercules,	  USA)	  were	  used	  as	  SDS-­‐PAGE	  markers.	  Following	  SDS-­‐PAGE,	  the	  
separated	   proteins	   were	   electro-­‐blotted	   onto	   polyvinyl	   difluoride	   (PVDF)	  
membranes	  (BIO-­‐RAD,	  Hercules,	  USA),	  running	  at	  15	  Volts	  for	  20	  minutes	  in	  cold	  
Tris-­‐glycine	  running	  buffer.	  After	  electro-­‐blotting,	  membranes	  were	  blocked	  for	  
60	  minutes	  using	  either	  5%	  (w/v)	  non-­‐fat	  skim	  milk	  (PAMS	  brand,	  New	  World	  ,	  
New	  Zealand)	  in	  Tris-­‐buffered	  saline	  and	  Tween20	  (TBS-­‐T)	  buffer	  or	  1%	  (w/v)	  
bovine	   serum	   albumin	   (BSA)	   in	   TBS-­‐T	   buffer.	   The	   blocking	   solution	   was	  
decanted	   off	   and	   diluted	   primary	   antibody	   solution	   was	   added	   prior	   to	  
incubation	   at	   4oC	   overnight.	   All	   primary	   antibodies	  were	   diluted	  50%	   (v/v)	   in	  
TBS-­‐T	   using	   the	   appropriate	   blocking	   solution.	   All	   antibodies	   were	   purchased	  
from	  Thermofisher	  Scientific,	  Rockford,	  IL,	  and	  their	  working	  concentrations	  are	  
described	  in	  Table	  2.1.	  
	  
The	   primary	   antibody	   solution	   was	   decanted	   off	   and	   the	   membranes	   were	  
washed	   by	   the	   addition	   of	   TBS-­‐T	   buffer,	   shaken	   on	   an	   orbital	   shaker	   for	   10	  
minutes,	  and	  decanting	  off	  of	  the	  TBS-­‐T	  buffer.	  This	  wash	  step	  was	  repeated	  four	  
times	   before	   the	   addition	   of	   the	   secondary	   antibody	   solution.	   As	   before,	   the	  
antibody	  solution	  was	  diluted	  50%	  (v/v)	  with	  TBS-­‐T	  buffer	  and	  the	  appropriate	  
blocking	   solution.	   Secondary	   antibodies	   were	   either	   anti-­‐rabbit-­‐goat	   or	   anti-­‐
mouse-­‐goat	   (see	   Table	   2.1	   for	   working	   concentrations).	   Membranes	   were	  
incubated	  with	  secondary	  antibody	   for	  90	  minutes	  at	   room	  temperature	  on	  an	  
orbital	   shaker.	   Following	   this	   incubation	   the	   secondary	   antibody	   solution	  was	  
discarded	  and	  the	  TBS-­‐T	  buffer	  wash	  step	  repeated	  (as	  before	  after	  the	  removal	  
of	   the	   primary	   antibody	   solution).	   A	   chemiluminescence	   detection	   kit	  
(AmershamTM	   ECLTM	   Prime	   Western	   Blotting	   Detection	   Reagent	   Kit,	   GE	  
Healthcare)	   was	   used	   to	   determine	   antibody	   localization.	   Protein	   bands	   were	  
visualized	   and	   densiometry	   analysis	   performed	   using	   Alliance	   4.7,	   Unitec	  
software	   (Cambridge,	   UK).	   Cell	   lysates	   were	   collected	   for	   each	   24-­‐hour	  
combination	  experiment	  (FR180204,	  LY294002,	  cisplatin	  and	  the	  combinations)	  





2.9 Statistical Analysis  
 
Statistical	   analyses	  were	  performed	  using	  GraphPad	  Prism®	   software	   (La	   Jolla,	  
CA,	  USA).	  Experimental	  results	  were	  assessed	  for	  significance	  using	  either	  one-­‐



























































Anti-­‐pERK	   PA5-­‐15305	   Mouse	   1/500	   1%	  (w/v)	  BSA	   1/5000	  
Anti-­‐Akt	   MA5-­‐
14916	  
Rabbit	   1/500	   1%	  (w/v)	  BSA	   1/1000	  















AHF0112	   Mouse	   1/500	   1%	  (w/v)	  BSA	   1/10,000	  
Anti-­‐cyclin	  
B2	  












CHAPTER 3: RESULTS  
 
3.1 Single Treatment Effects on Cellular Metabolism and Growth 
 
To	  assess	  cellular	  metabolism	  and	  cell	  growth	  of	  Hec-­‐1A	  and	  OVCAR-­‐5	  cell	  lines	  
following	   treatment	  with	   cisplatin,	   FR180204	  and	  LY294002,	  Alamar	  Blue	   and	  
crystal	   violet	   assays	   were	   used	   respectively.	   FR180204	   experiments	   were	   not	  
completed	  due	   to	   issues	  with	  contamination	  and	   time	  constraints	   -­‐	   see	   section	  
4.4	  for	  elaboration.	  
 
3.1.1 Cisplatin  
 
Overall,	   treatment	  with	  cisplatin	  did	  not	  significantly	  affect	  cellular	  metabolism	  
or	  growth	  activity	  in	  either	  cell	  line	  after	  24	  hours	  (Fig	  3.1.1	  a,	  b,	  c,	  d).	  There	  was	  
a	   trend	   for	   Hec-­‐1A	   cells	   to	   increase	   metabolism	   after	   24	   hours	   with	   cisplatin	  
treatment,	   although	   the	   increase	   was	   not	   statistically	   significant	   (P	   >	   0.05,	  
ANOVA,	  n	  =	  9)	  (see	  Fig.	  3.1.1	  a).	  Increased	  metabolism	  could	  indicate	  resistance,	  
as	   the	   anticipated	   metabolic	   reduction	   characteristic	   of	   cisplatin	   treatment	   is	  
absent.	  This	  is	  unexpected,	  although	  may	  require	  more	  replicates	  to	  confirm	  this	  
result.	  Cisplatin	  also	  affected	  cell	  growth	  of	  the	  Hec-­‐1A	  cells	  (see	  Fig	  3.1.1	  b),	  as	  
there	  was	  an	   increase	  after	  24	  hours	  with	   the	  5	  µM	  treatment.	  However,	  again	  
this	  was	  not	  a	  statistically	  significant	  result	   (P	  >	  0.05,	  ANOVA,	  n	  =	  9).	  Cisplatin	  
had	  little	  effect	  on	  the	  metabolic	  activity	  of	  the	  OVCAR-­‐5	  cells	  (P	  >	  0.05,	  ANOVA,	  
n	  =	  9)	  (Fig	  3.1.1	  c).	  However	  there	  was	  a	  trend	  toward	  reduction	  in	  cell	  growth	  
activity	  (see	  Fig	  3.1.1	  d)	  with	  both	  5	  µM	  and	  10	  µM	  cisplatin	  treatments	  having	  
an	  effect	  after	  24	  hours	  although	  again	  this	  was	  not	  statistically	  significant	  (P	  >	  









Figure	  3.1.1	  Single	  Treatment	  Effect	  of	  Cisplatin	  on	  Cellular	  Metabolism	  and	  
Growth.	  Relative	  cellular	  metabolism	  (determined	  by	  an	  Alamar	  Blue	  assay)	  (a)	  
and	  growth	  activity	  (determined	  by	  a	  crystal	  violet	  assay)	  (b)	  of	  Hec-­‐1A	  cells	  
treated	  with	  various	  concentrations	  of	  cisplatin	  for	  24	  hours.	  Data	  are	  from	  three	  
independent	  experiments	  carried	  out	  in	  triplicate	  ±	  SEM.	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Figure	  3.1.1	  Single	  Treatment	  Effect	  of	  Cisplatin	  on	  Cellular	  Metabolism	  and	  
Growth.	  Relative	  cellular	  metabolism	  (determined	  by	  an	  Alamar	  Blue	  assay)	  (c)	  
and	  growth	  activity	  (determined	  by	  a	  crystal	  violet	  assay)	  (d)	  of	  OVCAR-­‐5	  cells	  
treated	  with	  various	  concentrations	  of	  cisplatin	  for	  24	  hours.	  Data	  are	  from	  three	  
independent	  experiments	  carried	  out	  in	  triplicate	  ±	  SEM.	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3.1.2 LY294002; PI3K inhibitor 
 
Overall,	  LY294002	  treatment	  had	   little	  effect	  on	  cellular	  metabolism	  or	  growth	  
activity	  after	  24	  or	  48	  hours	  in	  either	  cell	  line	  (Fig	  3.1.2	  a,	  b,	  c,	  d).	  Figure	  3.1.2	  a	  
shows	  that	  there	  was	  no	  significant	  effect	  on	  cellular	  metabolism	  in	  the	  Hec-­‐1A	  
cells.	  In	  comparison,	  cell	  growth	  was	  largely	  unaffected	  (Fig	  3.1.2	  b),	  although	  it	  
was	  significantly	  decreased	  after	  24	  hours	  with	  the	  8	  µM	  treatment	  (P	  =	  0.0012,	  
ANOVA,	  n	  =	  9)	  and	  after	  48	  hours	  with	  the	  4	  µM	  treatment	  (P	  =	  0.0225,	  ANOVA,	  n	  
=	  9).	  Although	  both	  24	  and	  48	  hours	  results	  show	  there	  is	  a	  reduction	  in	  cellular	  
growth,	   because	   these	   are	   not	   consistent	  with	   the	   other	   data	   points	   (of	   either	  
longer	  duration	  at	  the	  same	  concentration	  or	  a	  higher	  concentration	  at	  the	  same	  
concentration),	   so	   these	   are	   difficult	   to	   explain.	   However	   there	   is	   a	   trend	  
towards	  a	  decrease	   in	  cell	  growth	  with	  all	   treatments.	  Further	  research	  and	  an	  
increase	   in	  replicates	  could	  clarify	  these	  results.	  OVCAR-­‐5	  cells	  showed	  a	  trend	  
towards	  a	  small	  decrease	  in	  cellular	  metabolism	  after	  treatment	  with	  LY294002	  
compared	   to	   the	   control	   (Fig	   3.1.2	   c)	   although	   of	   these	   only	   the	   24-­‐hour	  
exposure	  to	  4	  µM	  was	  statistically	  significant	  (P	  =	  0.0387,	  t-­‐test,	  n	  =	  3).	  As	  there	  
was	  no	  significant	  difference	  in	  metabolism	  at	  the	  higher	  concentrations	  (8	  µM)	  
this	   suggests	   that	   further	   experiments/replicates	   are	   required	   to	   clarify	   these	  
results	   (Fig	  3.1.2	  d).	  There	  was	  a	   trend	   for	  cell	  growth	  of	   the	  OVCAR-­‐5	  cells	   to	  
increase	   as	   the	   concentration	   of	   LY294002	   increases	   after	   24	   hours,	   although	  














Figure	  3.1.2	  Single	  Treatment	  Effect	  of	  LY294002	  on	  Cellular	  Metabolism	  and	  
Growth.	  Relative	  cellular	  metabolism	  (determined	  by	  an	  Alamar	  Blue	  assay)(a)	  
and	  growth	  activity	  (determined	  by	  a	  crystal	  violet	  assay)(b)	  of	  Hec-­‐1A	  cells	  
treated	  with	  various	  concentrations	  of	  LY294002	  for	  24	  hours	  (grey	  columns)	  or	  
48	  hours	  (blue	  columns).	  Data	  are	  from	  three	  independent	  experiments	  carried	  
out	  in	  triplicate	  ±	  SEM.	  *	  denotes	  a	  statistical	  significance	  (t-­‐test,	  P<	  0.05)	  relative	  
to	  the	  control.	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Figure	  3.1.2	  Single	  Treatment	  Effect	  of	  LY294002	  on	  Cellular	  Metabolism	  and	  
Growth.	  Relative	  cellular	  metabolism	  (determined	  by	  an	  Alamar	  Blue	  assay)(c)	  
and	  growth	  activity	  (determined	  by	  a	  crystal	  violet	  assay)(d)	  of	  OVCAR-­‐5	  cells	  
treated	  with	  various	  concentrations	  of	  LY294002	  for	  24	  hours	  (grey	  columns)	  or	  
48	  hours	  (blue	  columns).	  Data	  are	  from	  three	  independent	  experiments	  carried	  
out	  in	  triplicate	  ±	  SEM.	  *	  denotes	  a	  statistical	  significance	  (t-­‐test,	  P<	  0.05)	  relative	  
to	  the	  control.	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3.1.3 20 µM LY294002  
 
Due	  to	  the	  lack	  of	  any	  consistent	  significant	  effect	  of	  LY294002	  treatment	  at	  the	  
lower	  concentrations,	  a	  higher	  concentration	  range	  of	  8	  µM	  to	  20	  µM	  was	  tested	  
to	  investigate	  whether	  this	  would	  be	  more	  influential	  in	  affecting	  the	  cell	  lines.	  	  
	  
After	   treatment	   with	   20	   µM	   LY294002,	   both	   cell	   lines	   showed	   no	   significant	  
decrease	  in	  cellular	  metabolism	  (Fig	  3.1.3	  a).	  However,	  there	  was	  a	  decrease	  in	  
cellular	  metabolism	   in	   the	  OVCAR-­‐5	   cells	   after	   treatment	   of	   20	   µM	   LY294002,	  
this	  was	   not	   statistically	   significant	   (see	   Fig	   3.1.3	   b)(P	   >	   0.05,	   ANOVA,	   n	   =	   3).	  
Crystal	   violet	   assays	   could	   unfortunately	   not	   be	   completed	   due	   to	   time	  
constraints,	   but	   in	   order	   to	   have	   accurate	   results	   on	   the	   growth	   activity	   of	  
LY294002,	   both	   Alamar	   Blue	   and	   crystal	   violet	   assays	   are	   suggested	   to	   be	  


























Figure	   3.1.3	   Single	   Treatment	   Effect	   of	   LY294002	   (20µM)	   on	   Cellular	  
Metabolism.	  Relative	  cellular	  metabolism	  (determined	  by	  an	  Alamar	  Blue	  assay)	  
of	   Hec-­‐1A	   (a)	   and	   OVCAR-­‐5	   (b)	   cells	   treated	   with	   20	   µM	   of	   LY294002	   for	   24	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3.2 Comparison of 2D and 3D Cell Culture  
 
To	   investigate	   if	   the	  method	  of	   culturing	   the	   cell	   lines	   influences	   the	  way	   they	  
react	   to	   the	   inhibitors,	   2D	   and	   3D	   cultures	   treated	   with	   LY294002	   were	  
compared.	  	  
	  
Overall	  regardless	  of	  culturing	  technique,	   there	  was	  no	  significant	  difference	   in	  
cellular	  metabolism	  or	  growth	  activity	  following	  treatment	  with	  LY294002.	  The	  
Hec-­‐1A	   cell	   lines	   metabolism	   results,	   comparing	   2D	   and	   3D	   showed	   no	  
significant	  difference	  (Fig	  3.2	  a).	  However,	  the	  3D	  2	  µM	  treatment	  shows	  a	  trend	  
towards	   reduction,	   although	   this	   is	   not	   significant	   (P	   >	   0.05,	   ANOVA,	   n	   =	   3).	  	  
Similarly	  the	  cell	  growth	  activity	  results	  have	  one	  significantly	  reduced	  result	  of	  
2D	  4	  µM	  treatment	  (Fig	  3.2	  b)	  (P	  >	  0.05,	  ANOVA,	  n	  =	  3),	  again	  however	  this	  was	  
not	   significant.	   This	   is	   not	   consistent	   with	   the	   treatment	   causing	   a	   significant	  
effect	   on	   metabolism	   results	   either,	   which	   suggests	   this	   may	   be	   an	   anomaly.	  
Otherwise	   all	   other	  data	  points	   are	  very	   similar	   in	   results	  between	  2D	  and	  3D	  
cultures.	  	  
	  
The	  metabolism	  of	   the	  OVCAR-­‐5	  was	  reduced	  with	  the	  3D	  4	  µM	  treatment	  (Fig	  
3.2	  c)	  although	  statistically	  it	  was	  not	  significant	  (P	  >	  0.05,	  ANOVA	  n	  =	  3).	  This	  is	  
not	  consistent	  with	  the	  cell	  growth	  activity	  results,	  which	  showed	  no	  significant	  
reduction	  with	  any	  treatments	  or	  culturing	  method	  (Fig	  3.2	  d).	  This	  result	  may	  

















Figure	  3.2	  Comparison	  of	  2D	  and	  3D	  Cell	  Culture	  Effects	  on	  Cellular	  Metabolism	  
and	   Growth.	   Relative	   cellular	   metabolism	   (determined	   by	   an	   Alamar	   Blue	  
assay)(a)	  and	  growth	  activity	  (determined	  by	  a	  crystal	  violet	  assay)(b)	  of	  Hec-­‐1A	  
cells	   treated	  with	  various	   concentrations	  of	  LY294002	  and	  grown	   in	  2D	  plates	  
(grey	   columns)	   or	   3D	   plates	   (blue	   columns).	   Data	   are	   from	   one	   independent	  
experiment	  carried	  out	  in	  triplicate	  ±	  SEM.	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Figure	  3.2	  Comparison	  of	  2D	  and	  3D	  Cell	  Culture	  Effects	  on	  Cellular	  Metabolism	  
and	   Growth.	   Relative	   cellular	   metabolism	   (determined	   by	   an	   Alamar	   Blue	  
assay)(c)	   and	   growth	   activity	   (determined	   by	   a	   crystal	   violet	   assay)(d)	   of	  
OVCAR-­‐5	   cells	   treated	  with	   various	   concentrations	   of	   LY294002	   and	   grown	   in	  
2D	   plates	   (grey	   columns)	   or	   3D	   plates	   (blue	   columns).	   Data	   are	   from	   one	  
independent	  experiment	  carried	  out	  in	  triplicate	  ±	  SEM.	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3.3 Combination Treatment Effects on Cellular Metabolism and Growth  
 
Hec-­‐1A	  and	  OVCAR-­‐5	  cells	  were	  treated	  with	  four	  different	  combinations	  of	  
FR180204	  (8	  µM),	  LY294002	  (8	  µM)	  and	  cisplatin	  (10	  µM)	  to	  determine	  whether	  
or	  not	  the	  cells	  could	  be	  re-­‐sensitised	  to	  cisplatin	  by	  the	  inhibition	  of	  PI3K,	  ERK	  
and	  their	  downstream	  effectors	  by	  LY294002	  and	  FR180204	  respectively.	  Both	  
cellular	  metabolism	  and	  cell	  growth	  activity	  were	  measured	  as	  before	  using	  the	  
Alamar	  Blue	  and	  the	  crystal	  violet	  assays,	  respectively.	  	  
	  
Hec-­‐A1	  cells	  exhibited	  no	  increase	  or	  decrease	  in	  cellular	  metabolism	  after	  24	  
hours	  exposure	  to	  all	  treatments	  relative	  to	  the	  control	  (Fig	  3.3	  a).	  Cell	  growth	  
activity	  was	  decreased	  after	  24	  hours	  in	  Hec-­‐1A	  cells	  (Fig	  3.2	  b)	  with	  the	  
FR180204,	  LY294002	  and	  cisplatin	  combination	  treatment,	  which	  showed	  a	  
slight	  decrease	  in	  growth	  activity	  (P	  >	  0.05,	  ANOVA	  n	  =	  6).	  This	  is	  a	  promising	  
finding	  as	  this	  could	  be	  a	  result	  of	  dual	  inhibition	  re-­‐sensitising	  the	  cells	  to	  
cisplatin.	  But	  the	  Alamar	  Blue	  results	  showed	  no	  reduction	  in	  metabolism	  with	  
this	  treatment.	  
	  
The	  cellular	  metabolism	  of	  OVCAR-­‐5	  cells	  decreased	  in	  all	  treatments	  after	  24	  
hours	  (Fig	  3.3	  c).	  This	  was	  most	  marked	  with	  the	  treatment	  with	  FR180204	  and	  
cisplatin	  (P	  =	  0.0035,	  ANOVA	  n	  =	  6).	  Similarly	  to	  Hec-­‐A1	  cells,	  the	  OVCAR-­‐5	  cells	  
showed	  no	  decrease	  in	  cell	  growth	  activity	  with	  the	  combinatory	  treatments	  
after	  24	  hours	  (Fig	  3.3	  d).	  In	  fact	  all	  treatments	  resulted	  in	  increased	  cell	  growth	  
activity	  suggesting	  there	  needs	  to	  be	  alterations	  in	  drug	  treatment	  to	  achieve	  
inhibitory	  results.	  
	  
48-­‐hour	  combination	  experiments	  were	  planned	  but	  due	  to	  contamination	  and	  













Figure	  3.3	  Combination	  Treatment	  Effect	  on	  Cellular	  Metabolism	  and	  Growth.	  
Hec-­‐1A	  cells	  were	  subject	  to	  combination	  treatment	  of	  10	  μM	  cisplatin,	  8	  μM	  
FR180204	  and	  8	  μM	  LY294002.	  After	  24	  hours	  (grey	  columns)	  or	  48	  hours	  (blue	  
columns)	  of	  treatment,	  cellular	  metabolism	  and	  growth	  activity	  were	  analysed	  
by	  Alamar	  Blue	  (a)	  and	  crystal	  violet	  assays	  (b),	  respectively.	  Data	  from	  two	  

























































































Figure	  3.3	  Combination	  Treatment	  Effect	  on	  Cellular	  Metabolism	  and	  Growth. 
Hec-­‐1A	   cells	   were	   subject	   to	   combination	   treatment	   of	   10	   μM	   cisplatin,	   8	   μM	  
FR180204	  and	  8	  μM	  LY294002.	  After	  24	  hours	  (grey	  columns)	  or	  48	  hours	  (blue	  
columns)	   of	   treatment,	   cellular	  metabolism	   and	   growth	   activity	  were	   analysed	  
by	   Alamar	   Blue	   (c)	   and	   crystal	   violet	   assays	   (d),	   respectively.	   Data	   from	   two	  
independent	   experiments	   carried	   out	   in	   the	   triplicate	   ±	   SEM.	   *	   denotes	   a	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3.4 Protein Expression 
 
Western	  blotting	  was	  carried	  out	  to	  determine	  the	  expression	  of	  a	  number	  of	  cell	  
cycle	  and	  signalling	  proteins	  in	  OVCAR-­‐5	  and	  Hec-­‐1A	  cells	  after	  their	  exposure	  to	  
FR180204,	   cisplatin	   and	  LY294002	  over	  24	  hours.	   Cell	   cycle	  proteins	   included	  
cyclin	   D2	   (G1/S	   phase),	   cyclin	   B2	   (G2/M	   phase),	   and	   PCNA	   (proliferating	   cell	  
nuclear	  antigen,	  S	  and	  G2/M	  phase).	  The	  expression	  of	  these	  proteins	  was	  used	  
to	   analyse	   the	   impact	   of	   the	   drug	   treatments	   upon	   cell	   cycle	   progression.	   ERK	  
and	   its	  more	   active	   phosphorylated	   form,	   pERK,	   were	   examined	   to	   determine	  
whether	   or	   not	   ERK	   signalling	   was	   active	   in	   these	   cells.	   Additionally	   the	  
expression	  of	  PI3K	  pathway	  proteins;	  phosphoinositide-­‐3	  kinase	  (PI3K),	  Akt	  and	  
its	  active	  form,	  pAkt	  were	  investigated	  to	  determine	  their	  active	  within	  the	  cell	  
lines.	   Due	   to	   time	   and	   contamination	   constraints	   only	   two	   experiments	   (n=2)	  
using	   OVCAR-­‐5	   cells	   were	   assessed	   for	   the	   combination	   treatments	   after	   24	  
hours.	  Of	  the	  two	  Western	  blots,	  only	  one	  produced	  usable	  data,	  and	  within	  these	  
blots	  only	   three	  proteins	  produced	  readable	  bands.	  Therefore	   these	  results	  are	  
not	   statistically	   analysable.	   However,	   it	   does	   give	   a	   qualitative	   indication	   of	  
protein	  expression	  in	  cells	  treated	  with	  these	  drugs	  over	  a	  24	  hour	  period.	  The	  
glycolytic	   enzyme	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   (GAPDH)	   was	  
used	   as	   the	   reference	   housekeeping	   protein,	   due	   its	   relatively	   constant	  
expression	   despite	   changing	   cellular	   conditions.	   Ideally	   this	   would	   have	   been	  
quantitatively	   affirmed	   by	   the	   density	   of	   the	   GAPDH	   bands,	   unfortunately	   on	  
both	   occasions	   of	   experiments	   the	   GAPDH	   blots	   did	   not	   work.	   In	   further	  
research,	   it	   would	   be	   useful	   to	   utilise	   a	   second	   housekeeping	   protein	   such	   as	  
actin.	   Each	   well	   was	   loaded	   with	   10	   µg	   of	   protein,	   as	   determined	   using	   the	  
protein	  concentration	  of	  each	  cell	  lysate	  (see	  Appendix).	  	  
	  
Figure	   3.4	   shows	   the	   Western	   blot	   results	   for	   the	   OVCAR-­‐5	   cell	   line,	   with	  
combinatory	  drug	   treatments.	  Caution	   is	  advised,	  bearing	   in	  mind	   that	   there	   is	  
no	  statistical	  analysis	  due	  to	  only	  one	  replicate	  being	  completed.	  	  
	  
In	   the	  OVCAR-­‐5	  cell	   line,	  expression	  of	   the	  cell	   cycle	  protein	  cyclin	  B2	  remains	  
constant	   between	   the	   different	   concentrations	   of	   drugs.	   There	   is	   potentially	   a	  
slightly	  lower	  expression	  in	  the	  last	  treatment	  (8	  µM	  FR18204	  +	  8	  µM	  LY294002	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+	  10	  µM	  cisplatin).	  Akt	  expression	  is	  constant	  across	  all	  drug	  treatments	  also,	  the	  
weakest	  expression	  would	  be	  the	  8	  µM	  LY	  +	  10	  µM	  cisplatin,	  although	  this	  still	  
indicates	  Akt	  expression	  within	  the	  cells.	  Finally	  ERK	  protein	  expression	  shows	  
expression	  across	  all	  treatments	  apart	  from	  8	  µM	  FR	  +	  8	  µM	  LY	  +	  10	  µM	  cisplatin.	  
This	  treatment	  has	  no	  ERK	  band/	  expression.	  	  
	  
Across	  the	  board	  all	  three	  proteins	  blotted	  show	  relatively	  consistent	  expression	  
across	   varying	  drug	   treatments.	   The	  only	   treatment	   that	   has	   shown	  promising	  
results	  is	  the	  combination	  of	  LY,	  FR	  and	  cisplatin.	  Although	  if	  this	  combination	  is	  
effective	   in	   reducing	   protein	   expression	   considerably,	   it	   would	   be	   expected	   to	  
see	  some	  reduction	   in	  expressions	   in	  combinations	  with	  only	   two	  of	   the	  drugs.	  
Nevertheless,	   further	   replicates	   would	   be	   required	   to	   confirm	   this	   as	   well	   as	  































































Figure	  3.4	  Western	  blots	  of	  cell	  cycle	  protein	  cyclin	  B2,	  and	  signalling	  proteins	  
Akt	  and	  ERK	  in	  OVCAR-­‐5	  cells. Cells	  were	  treated	  with:	  8	  µM	  FR180204	  (FR),	  8	  
µM	   LY294002	   (LY)	   and	   10	   µM	   cisplatin	   (Cis)	   in	   varying	   combinations	   for	   24	  
hours.	   Images	   are	   representative	   of	   one	   experiment,	   10	  µg	   of	   protein	  per	  well	  







Control	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CHAPTER 4: DISCUSSION  
 
The	  aim	  of	  this	  study	  was	  to	  investigate	  FR180204	  and	  LY294002	  (ERK	  and	  PI3K	  
inhibitors	  respectively)	  and	  their	  efficacy	  in	  re-­‐sensitising	  resistant	  ovarian	  and	  
endometrial	  cells	  to	  cisplatin.	  Overall	  the	  study	  showed	  no	  successful	  inhibition	  
of	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway	  or	  the	  PI3K,	  Akt,	  mTOR	  pathway,	  singly	  or	  in	  
combination.	   Thus	   successful	   re-­‐sensitisation	   to	   cisplatin	   treatment	   was	   not	  
achieved.	  However,	  the	  information	  found	  has	  provided	  insights	  into	  alternative	  
approaches	   of	   pathway	   inhibition,	   and	   has	   built	   a	   platform	   for	   future	   studies	  
aimed	  at	  developing	  a	  novel	   combination	   therapy	   for	   cisplatin	   resistant	   cancer	  
cells.	  	  
 
4.1 Cisplatin Treatment Demonstrates Resistance in Hec-1A and OVCAR-5 cells  
 
Cisplatin	   treatment	   confirmed	  OVCAR-­‐5	   and	  Hec-­‐1A	   resistance	   to	   the	   first-­‐line	  
therapeutic	  drug.	  In	  response	  to	  the	  cisplatin	  treatment,	  no	  significant	  reduction	  
of	   cellular	   metabolism	   or	   growth	   activity	   after	   24	   hours	   of	   exposure	   was	  
observed.	  Previously	  Rosenberg	  and	  Vancamp	  (1969)	  found	  5	  µM	  cisplatin	  to	  be	  
effective	  in	  their	  studies	  of	  the	  platinum-­‐based	  agent.	  This	  concentration	  is	  also	  
relevant	   as	   it	   is	   the	   highest	   concentration	   that	   would	   be	   seen	   in	   vivo	   after	  
standard	  cisplatin	  treatment	  (Lerza	  et	  al	  1997,	  Rajan	  et	  al	  2009).	  Thus	  it	  is	  likely	  
that	  the	  OVCAR-­‐5	  and	  Hec-­‐1A	  cells	  are	  resistant	  given	  the	  higher	  concentrations	  
that	  they	  were	  exposed	  to	  in	  the	  current	  study.	  	  
 
4.2 PI3K Inhibition Did Not Prevent Cell Proliferation  
 
The	   PI3K	   pathway	   and	   its	   proteins	   are	   the	   subjects	   of	   numerous	   therapeutic	  
approaches,	   and	   the	  majority	   of	   success	   in	   clinical	   trials	   comes	   from	   targeting	  
either	   PI3K	   or	   mTOR	   proteins.	   This	   project	   used	   a	   broad-­‐PI3K	   inhibitor;	  
LY294002	  on	  the	  basis	  of	   its	  success	   in	  previous	  studies	  and	  evidence	  showing	  
its	  efficacy	  at	  varying	  concentrations;	  in	  particular	  with	  cancer	  cells	  (Gupta	  et	  al	  
2012,	   Yu	   et	   al	   2015).	   This	   inhibitor	   has	   featured	   in	   several	   studies	   using	   the	  
OVCAR-­‐5	   and	   Hec-­‐1A	   but	   these	   are	   limited	   (Altomare	   et	   al	   2004,	   Kang	   et	   al	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2012).	  However,	  it	  has	  been	  used	  against	  similar	  cell	  lines	  (i.e.	  OVCAR-­‐3,	  OVCAR-­‐
8),	  as	  well	  as	  cisplatin-­‐resistant	  cell	  lines,	  Thus	  it	  was	  hypothesized	  that	  it	  might	  
have	  similar	  effects	  against	  OVCAR-­‐5	  and	  Hec-­‐1A	  (Eckstein	  et	  al	  2009,	  Lee	  et	  al	  
2005,	  Mazzoletti	   et	  al	  2011).	  Previously	  preliminary	  observations	   from	  Schenk	  
(2013),	  suggested	  low	  levels	  of	  ERK	  expression,	  but	  conversely	  high	  levels	  of	  Akt	  
in	   the	   OVCAR-­‐5	   cell	   line	  when	   treated	  with	   an	   ERK	   inhibitor;	   FR180204.	   This	  
prompted	  the	   investigation	  of	  an	  alternate	  pathway	  (PI3K),	  and	  dual	   inhibition	  
of	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway	  and	  the	  PI3K,	  Akt,	  mTOR	  pathway	  in	  order	  to	  
re-­‐sensitise	  tumour	  cells	  to	  cisplatin.	  	  
	  
Single	   treatment	  with	  LY294002	  (2	  µM,	  4	  µM	  and	  8	  µM)	  showed	  no	  significant	  
decrease	  in	  cell	  metabolism	  or	  growth	  activity	  of	  cell	  lines	  after	  24	  or	  48	  hours	  of	  
exposure.	   It	   is	   difficult	   to	   explain	   this	   result	   given	   the	   abundance	   of	   literature	  
reporting	   its	   efficacy.	   Hu	   et	   al	   (2002)	   treated	   ovarian	   cancer	   cells	   (OVCAR-­‐3)	  
with	  5	  µM	  LY294002	  and	  found	  cell	  growth	  to	  decrease	  as	  well	  as	  inhibition	  of	  
PI3K.	  This	  would	  suggest	  that	  the	  concentration	  chosen	  in	  this	  study	  should	  have	  
been	  sufficient	  to	  elicit	  an	  effect.	  For	  this	  study	  it	  was	  decide	  to	  treat	  the	  cells	  at	  
low	   concentrations	   as	   there	   is	   evidence	   suggesting	   that	   the	   lower	   the	   drug	  
concentrations,	   the	   less	   likely	   there	   will	   be	   side	   effects	   in	   vivo	   if	   the	   therapy	  
makes	   it	   to	   clinical	   trials.	   It	   is	   of	   interest	   that	   Altomare	   et	   al	   (2004)	   treated	  
OVCAR-­‐4	  and	  OVCAR-­‐5	  cell	  lines	  with	  20	  µM	  LY294002	  and	  found	  it	  to	  have	  little	  
effect	   on	   the	   cells.	   They	   suggested	   that	   the	   cells	   constitutive	   activation	   of	   Akt	  
increased	  their	  resistance	  to	  cisplatin	  through	  protection	  from	  cisplatin-­‐induced	  
apoptosis.	  This	  could	  explain	  why	  OVCAR-­‐5	  cells	  did	  not	  respond	  to	  LY294002	  
treatment	   in	   this	   study.	   As	   for	   studies	   treating	   Hec-­‐1A	   cells	   with	   LY294002,	  
Gagnon	  et	  al	  (2004)	  found	  50	  µm	  treatment	  to	  reduce	  the	  expression	  of	  the	  Akt	  
protein	   and	   increase	   of	   apoptosis	  within	   these	   cells.	   This	   does	   not	   explain	   the	  
results	  found	  in	  this	  study.	  As	  there	  is	  the	  potential	  that	  the	  low	  concentrations	  
of	   LY294002	   were	   insufficient	   for	   the	   inhibition	   of	   the	   cell	   lines	   used	   in	   this	  
study	  a	  single	  experiment	  was	  completed	  testing	  the	  effect	  of	  20	  µM	  LY294002	  
on	   the	   OVCAR-­‐5	   and	   Hec-­‐1A	   cell	   lines.	   This	   experiment	   likewise	   showed	   no	  
significant	   decrease	   in	   cellular	   metabolism,	   though	   this	   experiment	   was	   only	  
carried	   out	   once	   due	   to	   time	   constraints	   and	   as	   such	   should	   be	   treated	   with	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caution.	  Previous	  research	  has	  shown	  that	  20	  µM	  is	  sufficient	  to	  inhibit	  PI3K	  and	  
to	  induce	  apoptosis	  in	  ovarian	  and	  endometrial	  cancer	  cells	  (Eckstein	  et	  al	  2009,	  
Yuan	   et	   al	   2000).	   In	   addition,	   Lee	   et	   al	   (2005)	   used	   25	   µM	   of	   LY294002	   on	  
ovarian	  cancer	  cells	  and	  this	  re-­‐sensitised	  them	  to	  cisplatin.	  With	  respect	  to	  Hec-­‐
1A	  cells,	  Guo	  et	   al	   (2006)	  around	  50	  µM	  of	  LY294002	   to	   inhibit	  Akt	   activation	  
and	  activity	  of	  the	  PI3K	  pathway.	  These	  studies	  suggest	  that	  it	  is	  possible	  to	  not	  
only	   use	   LY294002	   on	   ovarian	   and	   endometrial	   cancers	   at	   20	   µM	   and	   get	  
successful	  inhibition,	  but	  also	  that	  it	  can	  work	  in	  combination	  with	  cisplatin	  and	  
thus	   could	   work	   effectively	   as	   a	   therapy	   that	   reduces	   cisplatin	   resistance.	  
Without	  existing	  data	  and	  animal	  models,	  it	  is	  difficult	  to	  say	  what	  concentration	  
would	   be	   relevant	   in	   vivo,	   with	   respect	   to	   LY294002.	   There	   are	   clinical	   trials	  
involving	  LY294002	  but	  unfortunately	  it	  has	  a	  history	  of	  adverse	  side	  effects	  (as	  
do	   many	   PI3K	   inhibitors)	   and	   thus	   results	   using	   this	   drug	   in	   vivo	   are	   not	  
available	  as	  of	  yet	  (Turacli	  et	  al	  2015,	  Yu	  et	  al	  2015).	  	  
	  
Another	  variable	  in	  this	  experiment	  that	  may	  have	  influenced	  how	  the	  cell	  lines	  
reacted	   to	   the	   PI3K	   inhibitor	   is	   the	   time	   of	   exposure	   to	   the	   inhibitory	   agent.	  
Preferable	  treatments	  would	  be	  expected	  to	  begin	  working	  after	  24	  to	  48	  hours	  
and	  in	  some	  experiments	  there	  can	  be	  reduction	  in	  signalling	  pathways	  after	  as	  
little	   as	   6-­‐12	   hours	   exposure	   (Kang	   et	   al	   2012).	   However,	   it	   would	   still	   be	   of	  
interest	  to	  investigate	  the	  effect	  of	  increasing	  the	  exposure	  time	  to	  LY294002	  to	  
72	  or	  96	  hours,	  instead	  of	  24	  and	  48	  hours.	  
	  
Selective	  targeting	  of	  one	  pathway	  may	  result	  in	  compensatory	  up-­‐regulation	  in	  
another	   and	   vice	   versa	   (Cheaib	   et	   al	   2015).	   As	   Schenk	   (2013)	   suggested	  with	  
single	  FR180204	  exposures	  and	  as	   these	  results	   further	  support,	   there	   is	  more	  
than	  one	  factor	  influencing	  resistant	  cancers,	  thus	  dual	  inhibition	  was	  of	  interest.	  
 
4.3 Dual Pathway Inhibition Did Not Prevent Cellular Proliferation   
 
In	   the	  present	   study	   the	  combination	  experiments	  used	  8	  µM	  FR180204,	  8	  µM	  
LY294002	   and	   10	   µM	   cisplatin	   in	   various	   combinations,	   to	   investigate	   the	  
viability	   of	   dual	   inhibition	   in	   re-­‐sensitising	   cell	   lines	   to	   platinum-­‐based	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chemotherapy.	   Despite	   previous	   studies	   implicating	   re-­‐sensitisation	   with	   dual	  
inhibition	   or	   combination	   treatment	   the	   results	   from	   this	   experiment	   did	   not	  
show	   any	   significant	   reduction	   of	   cellular	   metabolism	   or	   cell	   growth	   activity	  
after	   24	   hours	   exposure.	   It	   had	   been	   hypothesised	   that	   the	   PI3K	   inhibitor,	   in	  
combination	  with	  the	  ERK	  inhibitor,	  would	  reduce	  any	  active	  pathway	  crosstalk	  
or	   protein	   over-­‐expression	   and	   reduce	   cell	   growth	   and	   metabolism	   to	   render	  
cells	   sensitive	   to	   the	   cisplatin	   treatment.	   As	   this	   was	   not	   the	   case,	   this	   may	  
suggest	  factors	  that	  are	  additional	  to	  signalling	  pathway	  proteins	  are	  influencing	  
cisplatin	   resistance	   in	   the	   cell	   lines	   that	  were	  used.	  Doghman	  and	  Lalli	   (2012)	  
used	  NVP-­‐BEZ235	  (a	  PI3K/mTOR	  inhibitor)	  in	  combination	  with	  FR180204	  and	  
found	  this	  duo	  to	  be	  synergistic	  and	  achieve	  efficient	  inhibition	  of	  adrenocortical	  
carcinomas	   proliferation.	   Yang	   et	   al	   (2013)	   also	   used	   this	   inhibitor	   in	  
combination	   with	   cisplatin	   upon	   human	   tumour	   cells	   and	   found	   it	   inhibited	  
proliferation	  and	  induced	  apoptosis.	  Dirican	  et	  al	  (2015)	  similarly	  to	  this	  study	  
used	  both	  FR180204	  and	  LY294002	  (concentrations	  not	  specified)	  to	  investigate	  
the	   possible	   synergistic	   apoptotic	   effects	   of	   combination	   treatment	   with	  
docetaxel	   and	   thymoquinone.	   They	   stated	   that	   a	  major	   benefit	   of	   combination	  
therapies	   is	   the	   ability	   to	   reduce	   the	   development	   of	   drug	   resistance,	   since	  
tumour	  cells	  are	  less	  likely	  to	  have	  resistance	  to	  multiple	  drugs	  simultaneously.	  
Interestingly,	  Dirican	  et	  al	   (2015)	   found	   that	  LY294002	  had	  no	  effect	  upon	   the	  
combination	   treated	   cells	   while	   FR180204	   did	   have	   an	   effect	   on	   the	   prostate	  
cancer	  cells,	  significantly	  decreasing	  their	  viability.	  This	  is	  somewhat	  relatable	  to	  
this	   study,	   as	   the	   cancer	   cell	   lines	   used	   also	   did	   not	   respond	   to	   LY294002.	  
however	  it	  differs	  from	  the	  effect	  of	  FR180204	  treatment	  in	  this	  study	  and	  also	  
from	  that	  of	  	  Schenk	  (2013).	  	  
	  
A	   theory	   discussed	   frequently	   in	   literature	   surrounding	   cisplatin	   and	   the	   Ras,	  
Raf,	  MEK,	  ERK	  pathway	  is	  ERK’s	  role	  in	  cisplatin-­‐induced	  apoptosis	  and	  cisplatin	  
resistance.	  There	  are	   studies	   supporting	   that	   cisplatin	   treatment	  activates	  ERK	  
and	   causes	   cisplatin-­‐induced	   apoptosis.	   On	   the	   other	   hand,	   there	   is	   literature	  
that	   suggests	   upstream	   proteins	   that	   are	   over-­‐expressed	   can	   increase	   ERK	  
activity,	  thus	  causing	  cisplatin	  resistance	  and	  the	  prevention	  of	  apoptosis.	  Wang	  
et	   al	   (2000)	   demonstrated	   that	   ERK2	   is	   activated	   by	   cisplatin	   and	   that	   this	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activation	  is	  necessary	  for	  cisplatin-­‐induced	  cell	  death.	  In	  comparison,	  Wang	  et	  al	  
(2007)	   found	   that	   knockdown	   of	   ERK2,	   decreases	   MPK-­‐1	   (mitogen-­‐activated	  
protein	   kinase	   1)	   phosphorylation	   and	   increases	   cisplatin	   sensitivity	   and	   thus	  
suggested	  that	  ERK	  protects	  ovarian	  cancer	  cells	  from	  cisplatin-­‐induced	  death.	  It	  
is	  possible	  that	  the	  pro-­‐death	  or	  the	  pro-­‐survival	  roles	  of	  MAPKs,	  like	  ERK	  may	  
depend	  on	  the	  type	  of	  activation	  signals	  it	  receives	  in	  order	  to	  commit	  to	  one	  of	  
these	  roles.	  Thus	  further	  investigation	  into	  the	  way	  cisplatin	  interacts	  with	  ERK	  
may	   elaborate	   how	   this	   protein	   is	   involved	   in	   both	   pro-­‐apoptotic	   and	   anti-­‐
apoptotic	  signalling	  (Wang	  et	  al	  2007).	  	  	  
	  
There	  is	  the	  possibility	  that	  the	  Ras,	  Raf,	  MEK,	  ERK	  pathway	  may	  not	  be	  critical	  
to,	   or	   involved	   in,	   cisplatin	   resistance	   in	   Hec-­‐1A	   and	   OVCAR-­‐5	   cells	   and	   that	  
oncogenes	  within	   the	  cell	   lines	  may	  have	  a	   role	   in	  FR180204’s	   lack	  of	   efficacy.	  
Both	  OVCAR-­‐5	  and	  Hec-­‐1A	  possess	  KRAS	  mutations	  but	  they	  do	  not	  carry	  BRAF	  
mutations	   and	   because	   of	   this	   it	   raises	   the	   question	   to	   whether	   or	   not	   KRAS	  
mutation	   is	   influencing	   pathways	   other	   than	   the	   Ras,	   Raf,	   MEK,	   ERK	   pathway	  
(Schenk	   2013).	   Certainly	   Ras	   has	   been	   shown	   to	   integrate	   between	   different	  
pathways	  and	  proteins	  within	  cells.	  There	  is	  the	  potential	   for	  another	  pathway,	  
such	   as	   JNK	   or	   p38	   MAPKs,	   to	   act	   in	   a	   similar	   fashion	   to	   ERK	   and	   to	   induce	  
cancer	  resistance,	  but	  at	  the	  same	  time	  to	  be	  unaffected	  by	  the	  inhibitors	  used	  in	  
this	  study.	  	  
	  
Signalling	   pathways	   are	   integrated	   into	   a	   complex	   network,	   and	   the	   final	  
response	  of	  a	  signal	  depends	  on	  the	  balance	  of	  activity	  of	  the	  pathways,	  the	  cell	  
type,	   proliferation	   and	   differentiation	   status	   of	   tumour	   cells	   (Brozovic	   and	  
Osmak	  2007).	  Thus,	   investigating	  signalling	  pathways	  can	  prove	  difficult,	  as	  for	  
the	   most	   part	   we	   still	   do	   not	   fully	   understand	   them	   and	   exactly	   how	   cellular	  
networks	  act	  in	  response	  to	  events	  such	  as	  chemotherapy	  induction.	  As	  such	  the	  
search	  for	  an	  effective	  and	  appropriate	  target	  for	  inhibition	  and	  re-­‐sensitisation	  
of	   cisplatin	   in	   cancer	   cells	   is	   complex.	   In	   addition,	   there	   is	   at	   present	   limited	  
research	  surrounding	  endometrial	  cancers	  and	  cisplatin,	  and	  combination	  drug	  
treatments,	  thus	  it	  is	  difficult	  to	  pin-­‐point	  what	  may	  be	  influencing	  resistance	  in	  
these	  cells.	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4.4 Analysis of PI3K and ERK Signalling 
 
Western	   blots	   demonstrated	   that	   the	   proteins	   ERK,	   Akt	   and	   cyclin	   B2	   were	  
expressed	  in	  OVCAR-­‐5	  cells.	  Cyclin	  B2	  expression	  in	  the	  ovarian	  cancer	  cells	  was	  
lowered	  after	  the	  8	  µM	  FR	  +	  8	  µM	  LY	  +	  10	  µM	  Cis	  treatment.	  This	  suggests	  the	  
cell	  cycle	  has	  been	  affected	  and	  that	  the	  dual	  inhibitors	  may	  have	  worked	  in	  re-­‐
sensitising	   the	  cells	   to	  cisplatin.	  However,	   these	  results	  are	  not	  consistent	  with	  
the	  growth	  data	  although	   it	  may	  be	   that	  a	   threshold	  decrease	   in	  protein	   levels	  
required	   for	   an	   effect	   on	   cell	   growth	   may	   not	   have	   been	   reached.	   Deng	   et	   al	  
(2003)	   found	   LY294002	   treatment	   to	   inhibit	   ovarian	   cancer	   cell	   proliferation,	  
and	  to	  induce	  G1	  cell	  cycle	  arrest.	  Although	  Deng	  et	  al	  (2003)	  did	  not	  investigate	  
cyclin	  B2	  expression;	  it	  suggests	  that	  the	  PI3K	  inhibitor	  has	  the	  ability	  to	  prevent	  
cell	   cycle	   activity	   in	   ovarian	   cancer	   cells.	   Further	   Western	   blots	   should	   be	  
completed	  involving	  cyclin	  D2,	  as	  these	  proteins	  are	  present	  across	  the	  entire	  cell	  
division	  process	  thus	  are	  a	  stronger	  indicator	  of	  cell	  cycle	  inhibition	  than	  cyclin	  
B2	  which	  is	  only	  expressed	  through	  G2/M	  phases	  (Deng	  et	  al	  2003).	  	  	  
	  
Akt	   protein	   expression	  was	   lowered	  by	   the	   8	   µM	  LY294002	  +	   10	   µM	   cisplatin	  
treatment.	   	   Altomare	   et	   al	   (2004)	   treated	   OVCAR-­‐5	   cells	   with	   LY294002	   and	  
observed	  diminished	  Akt	   phosphorylation.	   Although,	   as	   per	   above,	   the	   cellular	  
metabolism	  and	  growth	  activity	  assays	  showed	  no	  noticeable	  changes	  in	  the	  cells	  
after	  this	  particular	  treatment.	  Again	  there	  may	  be	  a	  required	  threshold	  decrease	  
that	  was	  not	  reached.	  	  
	  
ERK	   expression	   in	   OVCAR-­‐5	   cells	   appeared	   to	   be	   lower	   in	   comparison	   to	   Akt.	  
This	   supports	   findings	   from	   Schenk	   (2013)	   who	   found	   there	   to	   be	   high	  
expression	  of	  Akt	   in	  OVCAR-­‐5	  cells,	  with	   lower	   levels	  of	  ERK.	  The	  blot	   for	  ERK	  
shows	  a	  faint	  band	  with	  the	  8	  µM	  LY	  +	  10	  µM	  Cis	  treatment,	  and	  no	  band	  with	  the	  
8	  µM	  FR	  +	  8	  µM	  LY	  +	  10	  µM	  Cis	  treatment.	  This	  is	  unexpected	  as	  LY294002	  is	  a	  
PI3K	  protein	   inhibitor	  and	  has	  no	  specificity	   for	  any	  of	   the	  proteins	  within	   the	  
Ras,	   Raf,	   MEK,	   ERK	   pathway.	   However,	   there	   is	   a	   possibility	   that	   due	   to	  
convergence	   and	   cross	   talk	   between	   the	   two	   pathways	   PI3K	   inhibition	   may	  
indirectly	  affect	  ERK	  (Cheaib	  et	  al	  2015).	  This	  is	  supported	  by	  Jacob	  et	  al	  (2002)	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who	  suggested	  that	  ERK	  activation	  was	   in	  some	  way	  dependent	  upon	  the	  PI3K	  
protein	  within	  B	  cells.	  	  
	  
Further	   Western	   blot	   experiments	   are	   required	   to	   fully	   elucidate	   the	   effects	  
FR180204,	   LY294002	   and	   cisplatin	   have	   upon	   the	   OVCAR-­‐5	   and	   Hec-­‐1A	   cell	  
lines,	  although	   the	  data	  gathered	   in	   this	  experiment	  has	  given	  an	   idea	   towards	  
what	   may	   be	   happening	   within	   the	   cells	   growth	   and	   signalling	   pathways.	  	  
However	   it	   should	  be	  noted	   that	   all	   of	   these	   conclusions	  are	  based	  on	  a	   single	  
experiment	  and	  that	  the	  housekeeping	  proteins	  did	  not	  produce	  any	  bands.	  Thus	  
we	   are	   restricted	   to	   qualitative	   assessments	   of	   only	   single	   replicates	   and	  
therefore	   due	   caution	   is	   advised.	  Had	   there	   been	   no	   contamination	   issues	   and	  
thus	  sufficient	  time	  available	  to	  optimise	  the	  conditions	  of	  the	  Westerns	  and	  to	  
vary	  out	  replicates	  we	  may	  have	  been	  able	  to	  come	  to	  more	  solid	  conclusions.	  	  
	  
4.5 2D and 3D Cell Culture  
 
The	  comparative	  data	  from	  this	  study	  on	  2D	  and	  3D	  cell	  cultures	  and	  how	  these	  
may	  affect	   the	   response	  of	   cell	  metabolism	  and	  activity	   to	   inhibitors	   suggested	  
that	  there	  was	  no	  significant	  difference	  between	  the	  two	  cell	  cultures.	  That	  said,	  
it	   would	   have	   been	   preferable	   to	   have	   greater	   numbers	   of	   replicates	   to	  
strengthen	  any	  conclusions.	  However	  due	  to	  time	  constraints	  and	  significant	  and	  
continuing	  contamination	  issues	  this	  was	  not	  possible	  (see	  section	  4.6).	  2D	  and	  
3D	  cell	  culture	  was	  included	  in	  the	  present	  study	  as	  an	  aspect	  of	  the	  investigating	  
the	   effect	   that	   a	   cancer	   cells	   microenvironment	   has	   on	   its	   growth	   and	  
metabolism	   in	   the	   presence	   of	   inhibitors.	   3D	   cell	   culture	   is	   seen	   as	   a	   more	  
appropriate	  representation	  of	  the	  in	  vivo	  environment	  of	  a	  tumour	  cell	  compared	  
to	   a	   2D	   culture,	   thus	   making	   it	   an	   increasing	   popular	   technique	   in	   cancer	  
research	  (Adissu	  et	  al	  2007,	  Thoma	  et	  al	  2014).	  	  
	  
Traditionally	  2D	  cell	  culturing	  causes	  cells	  to	  lose	  their	  tissue-­‐specific	  functions	  
and	  morphological	  organization	  (Chitcholtan	  et	  al	  2013).	  3D	  cell	  cultures	  aim	  to	  
restore	  the	  3D	  architecture	  that	  characterises	  normal	  tissues	  and	  solid	  tumours.	  
It	   has	   been	   reported	   that	   3D	   multi-­‐cellular	   aggregates	   contain	   hypoxic	   and	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necrotic	  areas	  found	  in	  primary	  tumours	  and	  these	  are	  thought	  to	  be	  associated	  
with	  chemo-­‐resistance	  (Lee	  et	  al	  2013).	  Whether	  the	  cells	  are	  grown	  in	  a	  2D	  or	  
3D	  microenvironment	  will	  also	  impact	  on	  cell	  shape	  and	  the	  architecture	  of	  cell-­‐
cell	  adhesions.	  Although	  the	  results	  from	  this	  study	  did	  not	  show	  any	  differences	  
between	   the	   two	   types	   of	   culture,	   this	   is	   an	   area	   that	   warrants	   further	  
investigation.	  	  
	  
Lee	  et	  al	   (2013)	   investigated	  chemo-­‐sensitivity	   to	  cisplatin	  and	  paclitaxel	   in	  11	  
ovarian	  cancer	  cell	  lines	  and	  63%	  (7/11)	  of	  cell	  lines	  	  had	  significantly	  increased	  
survival	   rates	   against	   cisplatin	   in	   3D	   cultures.	   This	   suggests	   that	   cells	   in	   3D	  
cultures	  may	  more	  accurately	  reflect	  characteristics	  of	  primary	  human	  epithelial	  
ovarian	  cancer	  cells	  in	  vivo,	  but	  also	  be	  more	  resistant	  to	  chemotherapies	  as	  well.	  
These	  3D	  cultures	  are	  thus	  likely	  to	  be	  better	  for	  studying	  the	  underlying	  biology	  
of	   the	   disease	   (Lee	   et	   al	   2013).	   	   The	   importance	   in	   utilising	   alternative	   cell	  
culturing	  techniques	   is	   invaluable	  to	  cancer	  research.	  The	  more	  precise	   in	  vitro	  
microenvironments	   are	   developed	   to	   culture	   and	   grow	   cancer	   cells,	   the	   closer	  
we	   get	   to	   developing	  ways	   to	   treat	   these	   tumours.	   3D	   cell	   culture	   encourages	  
cell-­‐cell	   interactions,	  which	  are	   important	   for	  growth	  and	  metastasis	  as	  well	  as	  
drug	   resistance.	   This	   is	   highly	   relevant	   and	   important	  with	   respect	   to	   ovarian	  
and	   endometrial	   cancers	   which	   are	   have	   often	   metastasized	   to	   different	  
locations	   within	   the	   body	   when	   the	   patient	   is	   initially	   diagnosed	   with	   the	  
diseases	  (Zietarska	  et	  al	  2007).	  	  
	  
4.6 Obstructions in Research  
 
As	  mentioned	  in	  previous	  sections,	  there	  were	  factors	  that	  arose	  that	  prevented	  
the	  completion	  of	  all	   the	  planned	  experiments	   in	   this	  project.	  The	  main	  reason	  
behind	   this	  was	   cell	   culture	   contamination,	   and	   as	   a	   consequence	   of	   this,	   time	  
constraints	  prevented	  critical	  experiments	  from	  being	  completed.	  There	  was	  the	  
intention	  of	  completing	  48-­‐hour	  combination	  experiments,	  in	  addition	  to	  further	  
replicate	   the	   24-­‐hour	   combination	   experiment,	   but	   because	   of	   contamination	  
continuously	   arising	   this	   could	   not	   be	   achieved.	   FR180204	   3D	   treatment	  
experiments	  were	  also	  planned	  along	  with	  extensive	  western	  blot	  analysis.	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New	  cultures	  of	   cells	  were	  obtained	  on	  numerous	  occasions	   in	  order	   to	  collect	  
data	   for	  these	   intended	  combination	  experiments	  but	  the	  media	  would	  become	  
contaminated	  with	  bacteria	  and	  thus	  the	  cells	  were	  un-­‐usable.	  As	  a	  result	  when	  
contamination	   appeared	   the	   experiment	   was	   discontinued	   immediately.	   New	  
cells	  were	  obtained	  from	  Christchurch	  Hospital	  at	  the	  University	  of	  Otago	  School	  
of	  Medicine	  and	   the	  process	  of	   culturing	  was	   repeated.	  After	   the	   first	   round	  of	  
contamination,	  a	  complete	  clean	  of	  the	  culture	  room	  was	  completed,	  additionally	  
the	  CO2	   incubator	  was	   cleaned	  with	  ethanol	   (routinely),	   both	   flow	   laminar	   cell	  
culture	   hoods	   were	   cleaned	   with	   ethanol	   and	   detergent	   (TriGene)	   as	   well	   as	  
fumigated,	   the	   use	   of	   TriGene	   on	   top	   of	   70%	   ethanol	   was	   employed	   to	   wipe	  
down	  all	  apparatus	  before	  entering	  the	  hood.	  New	  base	  media,	  trypsin-­‐EDTA,	  1x	  
PBS	   and	   working	   media	   were	   freshly	   made	   on	   multiple	   occasions	   when	   they	  
were	   suspected	   to	  be	   the	   cause	  of	   contamination.	  New	  pipette	   tips	  with	   filters	  
were	  purchased	   to	  prevent	  any	  contamination	   from	  this	  apparatus.	  This	  action	  
appeared	   to	   resolve	   the	   problem	   for	   a	   few	   weeks	   but	   contamination	   would	  
eventually	   reappear.	   To	   ensure	   that	   poor	   aseptic	   technique	   was	   not	   a	  
contributing	   factor	   to	   the	   contamination,	   several	   researchers	   from	   the	  
laboratory	  observed	  aseptic	  techniques.	  Nothing	  obvious	  was	  seen	  that	  might	  be	  
the	   cause	   of	   the	   contamination.	   Another	   colleague	   within	   the	   laboratory	  
encountered	  similar	  contamination	  problems	  around	  the	  same	  time	  period	  and	  
additionally	   there	   have	   been	   previous	   contamination	   issues	   within	   in	   the	   lab	  
(A.Tino	  personal	  communication).	  It	  is	  suggested	  that	  future	  research	  should	  be	  
completed	   in	   a	   dedicated	  mammalian	   lab	   to	   reduce	   the	   cross	   over	   of	   research	  
between	   lab	   workers	   and	   allow	   for	   the	   precise	   elimination	   of	   causes	   of	  
contamination	  if	  it	  arises.	  As	  it	  currently	  stands	  research	  in	  this	  multi-­‐user	  lab	  is	  
currently	   carried	  out	  on	  mammalian	   cells,	   bacterial	   cells,	  plant	   cells,	   algal	   cells	  







4.7 Targeting Alternative Signalling Pathways  
 
As	  mentioned	   previously	   there	   are	   potential	   alternative	   growth	   and	   signalling	  
pathways	   that	   may	   influence	   a	   cancer	   cells	   resistance	   to	   cisplatin.	   Pleiotropic	  
interactions	   with	   other	   parallel	   pathways,	   or	   interacting	   proteins	   may	   allow	  
tumour	  cells	  to	  escape	  from	  PI3K	  inhibition.	  The	  published	  literature	  describing	  
Akt’s	  interactions	  with	  Ras	  as	  well	  as	  Ras’	  interaction	  with	  the	  likes	  of	  JNK,	  P38-­‐
MAPK	   and	   PKC	   proteins	   and	   pathways,	   may	   be	   pertinent	   to	   the	   responses	   of	  
OVCAR-­‐5	  and	  Hec-­‐1A	  cells	  that	  are	  reported	  in	  this	  study.	  	  
	  
SAPK/JNK	  (or	  stress	  activated	  protein	  kinase/Jun	  N-­‐terminal	  kinase)	  is	  a	  serine-­‐
threonine	   kinase,	   which	   is	   activated	   in	   response	   to	   cellular	   stress	   (i.e.	   UV	  
radiation,	  cytotoxic	  drugs	  and	  reactive	  oxygen	  species	  (ROS)).	  Mammalian	  cells	  
have	  3	  JNK	  genes;	  JNK1,	  JNK2	  and	  JNK3	  and	  have	  at	  least	  10	  isoforms	  (Brozovic	  
and	  Osmak	  2007).	  JNK1/2	  phosphorylates	  the	  N-­‐terminus	  of	  its	  substrate	  c-­‐Jun.	  
Phosphorylation	  of	  c-­‐Jun	  increases	  the	  activation	  of	  AP-­‐1	  (a	  transcription	  factor	  
that	   enhances	   gene	   expression),	   which	   can	   influence	   processes	   such	   as	  
proliferation,	  differentiation	  and	  apoptosis.	  Both	   JNK	  and	  ERK	  are	  activated	  by	  
cisplatin-­‐induced	  DNA	  damage	  and	  are	  required	   for	  cell	   survival	  after	  cisplatin	  
treatment	   (Hayakawa	   et	   al	   2000).	   It	   is	   suggested	   that	   future	   studies	   could	  
investigate	  the	  JNK	  pathway,	  as	  the	  literature	  suggests	  its	  activity	  to	  be	  similar	  to	  
that	  of	  ERK	  and	  its	  associations	  with	  cancer.	  Another	  MAPK	  pathway	  that	  may	  be	  
pertinent	   is	   the	   p38/MAPK	   pathway.	   Rho	   family	   GTPases	   activate	   the	   p38	  
protein.	   Following	   activation,	   several	   protein	   kinases	   are	   activated	   through	  
phosphorylation.	  	  P90MAPKAPK2	  and	  MSK1/2	  phosphorylation	  lead	  to	  activation	  of	  
transcription	   factors	   (i.e.	   CREB)	   that	   regulate	   cell	   survival.	   The	   duration	   of	  
activated	   JNK	   and	  p38	   signal	   is	   a	   critical	   factor	   in	   determining	   cell	   survival	   or	  
apoptosis.	   Resistance	   is	   due,	   in	   part,	   to	   lack	   of	   prolonged	   activation	   of	   these	  
stress	  kinases	  (Mansouri	  et	  al	  2003).	  This	  could	  also	  be	  the	  case	  with	  ERK	  and	  
may	  be	  a	  factor	  in	  why	  this	  study	  did	  not	  observe	  inhibition.	  	  
	  
Ras,	  Raf,	  MEK,	  ERK	  and	  PI3K,	  Akt,	  mTOR	  pathways	  can	  negatively	  regulate	  each	  
other’s	   activity.	   Evidence	   of	   this	   includes	   IGF-­‐1	   (insulin	   growth	   like	   factor	   1)	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inducing	   cross-­‐inhibition	   between	   Akt	   and	   Raf	   and	   additionally	   Akt	   can	  
negatively	   regulate	   ERK	   activity	   through	   phosphorylating	   inhibition	   sites	   on	  
Raf’s	  N-­‐terminus	  (Mendoza	  et	  al	  2011).	  In	  addition,	  once	  ERK,	  RSK,	  Akt	  and	  S6K	  
proteins	  are	  active,	  any	  of	  these	  can	  act	  upon	  the	  same	  substrate,	  sometimes	  in	  
concert,	   to	   promote	   cell	   survival,	   proliferation,	   metabolism	   and	   motility.	   Ras	  
proteins	   have	   strong	   interactions	   with	   both	   the	   PI3K	   and	   ERK	   pathways,	  
influencing,	   and	   indirectly	   interacting	   with	   the	   majority	   of	   proteins	   involved	  
within	   these	   pathways.	   For	   example	   Ras-­‐ERK	   interaction	   can	   lead	   to	  mTORC1	  
activity	   by	   ERK,	  whilst	   Akt	   can	   be	   phosphorylated	   via	   crosstalk	  with	   Ras	   also	  
(Cheaib	  et	  al	  2015).	  	  
	  
Similarly	   to	   Ras,	   it	   is	   thought	   that	   signalling	   molecules	   and	   receptors	   that	  
activate	  the	  pathways	  discussed	  may	  be	  potential	  targets	  for	  inhibition.	  This	  idea	  
is	   especially	   pertinent	   to	   endometrial	   cancers,	   where	   EGFR	   is	   commonly	   up	  
regulated,	   and	   thus	   could	   be	   influencing	   the	   tumour	   cells	   activity	   or	   cellular	  
signalling	   pathways	   (Jayson	   et	   al	   2014).	   One	   inhibitor	   that	   has	   already	   been	  
developed	   and	   is	   in	   clinical	   trials	   is	   Bevacizumab.	   This	   is	   a	   humanised	  
monoclonal	  antibody	  used	  against	  VEGF.	  It	  did	  not	  have	  great	  results	  in	  phase	  II	  
trials,	   but	   has	   recently	   shown	   big	   improvements	   in	   survival	   in	   lung	   cancer	  
patients	   and	   has	   been	   treated	   on	   platinum	   resistant	   cancers	   with	   docetaxel	  
(Kelland	  2007,	  Wenham	  et	  al	  2013).	  Another	   factor	   commonly	  associated	  with	  
endometrial	  cancer	  is	  high	  levels	  of	  insulin.	  Insulin	  binding	  to	  an	  insulin	  receptor	  
triggers	  the	  activation	  of	  IRS-­‐2	  and	  activates	  PI3K/Akt	  pathways	  (Slomovitz	  and	  
Coleman	  2012).	  	  
	  
The	  key	  point	  to	  take	  away	  from	  all	  of	  the	  above	  is	  that	  resistance	  is	  likely	  to	  be	  
highly	  multi-­‐factorial.	   This	   is	  well	   put	   by	   Siddik	   (2003)	  who	   state	   that	   several	  
mechanisms	  are	  encountered	  simultaneously	  within	   the	   same	   tumour	  cell,	   and	  
that	   a	   high	   level	   of	   resistance	   is	   a	   net	   effect,	   of	   several	   unrelated	  mechanisms	  




4.8 Considerations for Future Research Endeavours  
 
As	   described	   above	   a	   number	   of	   experiments	   could	   not	   be	   done	   due	   to	   the	  
significant	  contamination	   issues.	  These	   included	  a	  comprehensive	   investigation	  
of	  protein	  expression	  using	  Western	  blot	  analysis.	  This	   is	  highly	  recommended	  
to	   continue	   investigating,	   as	   it	   would	   not	   only	   ultimately	   show	   whether	   the	  
inhibitors	  were	  effective	  or	  not,	  but	  also	  give	  an	  insight	   into	  how	  the	  signalling	  
pathways	  were	  reacting	  to	  the	  treatments.	  	  
	  
As	  mentioned	  prior	  experiments	  treating	  the	  cell	  line	  with	  higher	  concentrations	  
of	   inhibitors	  would	  be	  beneficial,	   as	  well	  as	  exposing	   the	  cells	   to	   the	   inhibitors	  
for	  an	  increased	  time	  period	  of	  up	  to	  96	  hours.	  	  
	  
Another	  idea	  to	  come	  out	  of	  the	  single	  treatment	  experiments	  was	  the	  potential	  
of	  using	  alternative	  inhibitors,	  instead	  of	  LY294002	  or	  FR180204.	  An	  example	  of	  
this,	  which	   is	  mentioned	   frequently	   in	   the	   literature,	   is	   PI3K/mTOR	   inhibitors.	  
Serra	  et	  al	  (2008)	  recommend	  the	  use	  of	  NVP-­‐BEZ275	  (a	  PI3K/mTOR	  inhibitor)	  
that	  successfully	  blocks	  cellular	  proliferation.	  A	  PI3K/mTOR	  inhibitor	  works	  by	  
inhibiting	  both	  PI3K,	  and	  mTOR.	  This	  is	  important	  as	  mTOR	  is	  not	  only	  under	  the	  
control	   of	   PI3K,	   but	   integrates	   many	   other	   inputs	   from	   outside	   factors,	   thus	  
highlighting	   the	   downside	   to	   using	   a	   PI3K	   specific	   inhibitor	   (Dienstmann	   et	   al	  
2014).	   	  Sheppard	  et	  al	   (2013)	  used	   the	  PI3K/mTOR	   inhibitor,	  PF502	  alongside	  
PD901	   (a	  MEK	   inhibitor)	   as	   a	   dual	   inhibition	   system	  and	   found	   a	   reduction	   in	  
proliferation	   of	   OVCAR-­‐5	   cells	   (Engelman	   2009).	   This	   provides	   encouraging	  
results	   as	   this	   inhibitor	   is	   shown	   to	  work	  effectively	  with	  other	   inhibitors	   in	   a	  
dual	   system	  as	  well	  as	  working	   to	  effectively	   inhibit	  proliferation	  of	  one	  of	   the	  
cell	  line	  used	  in	  this	  study.	  	  
	  
An	  undesirable	  outcome	  of	  inhibition	  and	  development	  of	  cancer	  treatment,	  are	  
in	   vivo	   side	   effects	   to	   the	   drugs.	   An	   example	   of	   this	   is	   the	   pharmaceutical	  
inhibition	  of	  Akt,	  which	  has	   the	  potential	   to	   impact	  glucose	  metabolism,	  due	  to	  
Akt’s	   critical	   role	   in	   insulin	   signalling	  and	  maintenance	  of	   glucose	  homeostasis	  
(Altomare	   et	   al	   2004,	   Whiteman	   et	   al	   2002).	   One	   potential	   approach	   to	  
 72 
minimising	  toxicity	  when	  targeting	  pathways	  is	  to	  selectively	  inhibit,	  for	  example	  
only	   those	  Akt	   isoforms	  within	  a	   specific	   tumour	   that	  have	  proven	   to	  promote	  
tumour	  progression	  (Hanrahan	  et	  al	  2012).	  This	   idea	  proposed	  is	  something	  to	  
investigate	  once	  signalling	  pathways	  or	  individual	  proteins	  within	  these	  specific	  
cell	  lines	  are	  identified	  as	  causes	  of	  resistance,	  then	  more	  specific	  treatments	  can	  
be	  developed	   to	   target	  particular	  overactive	  proteins	  or	   even	   specific	   isoforms	  
for	  each	  cell	  line.	  	  
	  
With	  future	  development	  of	  drugs	  hopefully	  comes	  a	  reduction	  in	  side	  effects	  or	  
that	   the	  use	  of	   effective	   combination	   therapies	  will	  possibly	   reduce	   this.	  When	  
drugs	  with	  different	  effects	  are	  combined,	  each	  drug	  can	  be	  used	  at	   its	  optimal	  
dose,	   without	   intolerable	   side	   effects.	   This	   was	   the	   desired	   idea	   behind	   this	  
study,	  using	  lower	  concentration	  to	  reduce	  the	  likelihood	  of	  adverse	  side	  effects	  
in	  vivo.	  This	  is	  why	  this	  research	  used	  lower	  levels	  of	  inhibitors	  to	  begin	  with,	  as	  
the	   idea	   of	   having	   the	   lowest	   level	   of	   inhibitor	   needed	   to	   sensitise	   cells	   to	  
cisplatin	   is	   ideal	   for	   reducing	   the	   amount	   of	   toxic	   side	   effects,	   and	   may	   even	  
allow	  the	  reduction	  in	  cisplatin	  treatment	  also.	  	  
	  
There	  is	  the	  possibility	  for	  future	  research	  following	  this	  study	  to	  use	  alternative	  
cell	  viability	  assays	  (Kepp	  et	  al	  2011).	  Although	  crystal	  violet	  is	  a	  method	  that	  is	  
relatively	   accurate,	   over	   time	   it	   has	   been	   largely	   superseded	   by	  more	  modern	  
options,	   which	   provide	   faster	   and	   more	   accurate	   results	   of	   cell	   numbers	   and	  
cellular	   death.	   The	   first	   and	  most	   commonly	   used	   option	   is	   propidium	   iodide	  
staining	   (Sheppard	   et	   al	   2013).	   This	   dye	   is	   membrane	   impermeable	   thus	   is	  
generally	  excluded	   from	  viable	   cells	   and	  only	   stains	  dead	  cells	   (Martinelli	   et	   al	  
2013).	   This	   test	   also	   can	   differentiate	   between	   necrotic,	   apoptotic	   and	   normal	  
cells.	  Another	  option,	  which	  utilises	  a	  dye,	  is	  trypan	  blue.	  Similarly	  to	  propidium	  
iodide,	  is	  not	  absorbed	  through	  the	  membrane	  of	  live	  cells.	  It	  only	  traverses	  the	  
membrane	  of	  dead	   cells,	   and	   these	   can	   then	  be	  observed	  and	   counted	   through	  
microscopy	  (Dirican	  et	  al	  2015).	  	  Again	  another	  dye	  used	  to	  stain	  dead	  cells	  is	  7-­‐
aminoactinomycin	  D,	  this	  chemical	  compound	  has	  a	  strong	  affinity	  for	  DNA	  and	  
is	   used	   as	   a	   fluorescent	  marker	   for	   DNA	   in	   fluorescence	  microscopy	   and	   flow	  
cytometry	   as	   it	   cannot	   pass	   through	   intact	   cell	   membranes	   like	   many	   others	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(Zembruski	  et	  al	  2012).	  	  Another	  way	  of	  measuring	  cell	  death	  is	  through	  lactate	  
dehydrogenase	   (LDH)	   expression.	   This	   enzyme	   is	   found	   in	   cells	   membranes	  
catalysing	   the	   reaction	   between	   lactate	   and	   pyruvic	   acid.	   It	   is	   readily	   detected	  
when	   cell	  membranes	   are	   no	   longer	   intact	   (Doherty	   and	  Cleveland	  2013).	   The	  
final	  method	  is	  the	  Annexin	  A5	  affinity	  assay	  (Martinelli	  et	  al	  2013).	  This	  is	  used	  
to	  quantify	  the	  number	  of	  cells	  undergoing	  apoptosis.	  Annexin	  A5	  is	  used	  to	  tag	  
apoptotic	  and	  dead	  cells,	  and	  the	  numbers	  are	  counted	  either	  by	  flow	  cytometry	  
or	   fluorescence	   microscopy.	   Having	   the	   ability	   to	   use	   a	   more	   precise	   and	  
accurate	  tests	  would	  aid	  the	  results	  of	  dual	   inhibition,	   in	  particular	  providing	  a	  





In	   conclusion	   this	   study	   has	   demonstrated	   that	   both	   the	   single	   treatments	   of	  
LY294002	  and	  combination	  treatments	  using	  FR180204	  and	  LY294002	  are	  not	  
effective	   in	   rendering	   Hec-­‐1A	   or	   OVCAR-­‐5	   cell	   lines	   sensitive	   to	   cisplatin.	   The	  
most	   plausible	   explanations	   for	   this	   are	   that	   the	   concentrations	   of,	   and/or	  
duration	  of	  exposure	  to,	  LY294002	  were	  too	  low/short	  to	  elicit	  an	  effect	  in	  these	  
cells,	   or	   there	   could	   be	   the	   involvement	   of	   alternate	   pathway	   proteins.	   The	  
results	   of	   this	   study	   add	   to	   research	   surrounding	   cisplatin	   resistance	   and	   the	  
treatments	  being	  developed	  to	  combat	  it.	  This	  research	  may	  not	  have	  fully	  tested	  
the	  hypotheses	  set	  out	  and	  provided	  the	  basis	  for	  a	  novel	  combination	  therapy,	  
though	   none	   the	   less	   it	   has	   resulted	   in	   the	   opportunity	   to	   investigate	   various	  
approaches	  in	  the	  future	  that	  have	  the	  potential	  to	  provide	  information	  towards	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Protein Concentration of Cell Lysates 
 
Prior to Western blotting the concentration of each cell lysate was used to determine 
the volume required to load 10 µg of protein for each treatment. This was achieved by 
generating a standard curve using known concentrations of BSA (Figure A1). 
Absorbances at 562 nm of protein samples with working reagent added were 
measured and used to determine the protein concentration via the standard curve. 
Protein concentration was then used to determine the volume for 10 µg of protein for 















































Figure A1: Standard	   curve	   generated	   for	   determining	   protein	   concentrations	   of	  
the	   OVCAR-­‐5	   cell	   lysates	   treated	   with	   varying	   combinations	   of	   FR180204,	  
LY294002	  and	  cisplatin	  for	  24	  hours.	  Curve	  was	  generated	  using	  BSA	  standards	  
of	  known	  concentration,	  measuring	  at	  562	  nm	  of	  standards	  mixed	  with	  working	  























Table A1: Absorbance	   of	   cell	   lysates	   mixed	   with	   working	   reagent	   at	   562	   nm,	  
subsequent	  protein	  concentration,	  and	  volume	  required	  for	  10	  µg	  of	  protein	  per	  
sample	   for	   OVCAR-­‐5	   cells	   treated	   with	   various	   concentrations	   of	   FR180204,	  






Control 8 µM 
FR180204 








+ 10 µM 
cisplatin 
8 µM 







287 139.2 176.8 154.6 505 
Replicate 
#2 






180 50.6 175.2 337 209.4 
Replicate 
#1 
0.287 0.1392 0.1768 0.1546 0.505 
Replicate 
#2 





0.180 0.0506 0.1752 0.337 0.2094 
Replicate 
#1 
34.84 71.83 56.56 64.68 19.80 
Replicate 
#2 






55.55 197.62 57.07 29.67 47.75 
 
 
 
 
 
 
 
 
 
	  
